The QualityStocks Daily Tuesday, August 11th, 2020

Today's Top 3 Investment Newsletters

QualityStocks (LLLI) +81.25%

SmallCapRelations (MCOA) +80.00%

MarketClub Analysis (PFNX) +67.49%

The QualityStocks Daily Stock List

FreightCar America, Inc. (RAIL)

FreightWaves, Railway-News, Railway Age, Progressive Railroading, Stocktwits, Zacks, Stocklight, TMXmoney, CSI Market, Stocknews, Investing.com, Seeking Alpha, InvestorsHub, Stockhouse, Market Screener, MacroTrends, MarketBeat, Business Insider, Annual Reports, Morningstar, Business Wire, MarketWatch, YCharts, GlobeNewswire, Nasdaq, Equities.com, Equity Clock, Simply Wall St, and GuruFocus reported previously on FreightCar America, Inc. (RAIL), and today we report on the Company, here at the QualityStocks Daily Newsletter.

FreightCar America, Inc. manufactures a wide variety of railroad freight cars, supplies railcar parts, and leases freight cars through its FreightCar America Leasing Company subsidiaries. It designs and builds high-quality railcars. These include bulk commodity cars, covered hopper cars, intermodal and non-intermodal flat cars, mill gondola cars, coil steel cars, boxcars, and coal cars. The Company’s customers primarily include railroads, shippers, and financial institutions.

Established in 1901, FreightCar America is headquartered in Chicago, Illinois. It also has facilities in Cherokee, Alabama; Grand Island, Nebraska; Johnstown, Pennsylvania; and Shanghai, People’s Republic of China (PRC). FreightCar America lists on the NasdaqGS.

FreightCar America has a large, in-stock inventory of high-quality forged, cast, and fabricated parts for all freight car types, regardless of the original builder. This includes open top hoppers, covered hoppers, auto carriers, gondolas, intermodal flat cars, box cars and more.

The Company can analyze part specs, examine rebuild options, or offer unique solutions for every type of railcar that it builds. FreightCar America’s custom fabrication and manufacturing expertise allow it to meet customers’ repair needs, and to develop new innovations such as its Coil Covers, Forged Knuckles, as well as Electronic Door Openers.

Yesterday, FreightCar America reported results for Q2 ended June 30, 2020. It had Q2 Revenue of $17.5 million on deliveries of 100 railcars. Its Q2 Net Loss was $12.8 million, or $0.97 per share. Q2 Backlog totaled 1,839 railcars, with an aggregate value of roughly $207 million.

In July, FreightCar America began production at the Castaños, Mexico joint venture (JV) facility. The Company’s second half 2020 delivery outlook is forecasted to range between 750 and 1,000 railcars.

Mr. Jim Meyer, President and Chief Executive Officer of FreightCar America, said, “Our overall production ramped well through July, giving us confidence in our forecast for second half deliveries to range between 750 and 1,000 railcars. As we look forward, we remain equally focused on preserving our liquidity while also continuing to build the foundation for our future. We believe we are taking the right steps to navigate both the cyclical downturn and pandemic, while repositioning FreightCar America for future success.”

FreightCar America, Inc. (RAIL), closed Tuesday's trading session at $1.78, off by 17.2093%, on 538,831 volume with 1,432 trades. The average volume for the last 3 months is 188,071 and the stock's 52-week low/high is $0.730000019/$5.67000007.

chart

Mandalay Resources Corporation (MNDJF)

Market Screener, Wallmine, Mining Capital, Dividend Investor, The Prospector News, Proactive Investors, GlobeNewswire, Northern Miner, TMXmoney, MarketBeat, Morningstar, Stockwatch, Junior Mining Network, OTC Markets, Wallet Investor, TradingView, Newswire, and hot Stocked reported previously on Mandalay Resources Corporation (MNDJF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

A natural resource company, Mandalay Resources Corporation has producing assets in Australia and Sweden, and care and maintenance and development projects in Chile. The OTCQB-listed Company is focusing on increasing production at its gold and antimony operation in Australia, and gold production from its operation in Sweden to produce near-term cash flow. Its mission is to create shareholder value through the acquisition of undervalued assets that can become rapidly cash generative, self fund exploration, establish and maintain high operating margins, and return cash to shareholders. Incorporated in 1997, Mandalay Resources is headquartered in Toronto, Ontario.

The Company operates the 100 percent-owned Costerfield gold-antimony mine in Victoria, Australia. It purchased the mine on December 1, 2009, from Western Coal.

Mandalay Resources acquired 100 percent interest in the Björkdal (Birch Valley) gold mine in September 2014, when it purchased 100 percent of Elgin Mining. Björkdal is situated in northern Sweden, one of the best mining jurisdictions worldwide. Björkdal produces gold from a combined open pit and underground operation with about 60 percent of plant feed currently delivered from the underground.

This past June, Mandalay Resources reported on the initial encouraging results of its regional testing programs and high-grade resource extensions in the Youle and Aurora ore bodies at its Costerfield operation in Victoria, Australia, and its Björkdal operation in Skellefteå, Sweden, respectively. Regarding Costerfield, the Company has had early success in the regional drilling program with significant intercepts in the first drill hole into Brown’s prospect (14.5 g/t gold, over a true width of 1.27 m and 23.5 g/t gold over a true width of 0.12 m in BWN001 (first hole in the testing program)). The high-grade Youle ore body extends to the north with substantial grades intercepted.

Regarding Costerfield, since the Company’s last update in January of this year, Mandalay Resources has increased drilling rates on the Youle extension program and started the already successful regional resting programs. The anticipated second deep drill hole underneath the central Costerfield system has also started.

Regarding Björkdal, drilling results show high-grade extension at depth in Aurora with additional extension potential to the east. Furthermore, northern drilling has intercepted three zones exhibiting high-grade intercepts. Since Mandalay’s last update in January of this year, the Company has continued to focus on the lateral and vertical extensions of the Aurora zone, and also the further investigation into the progression of the mineralized package to the North of present operations. In addition, an additional extensional program was completed in January of 2020, targeted at the down dip extension of skarn mineralization observed in the open pit.

Mandalay Resources’ Q2 2020 financial results will be released after market close on August 12, 2020, followed by a conference call with Mr. Dominic Duffy, President and Chief Executive Officer of the Company, for investors and analysts on August 13, 2020, at 8:00 AM (Toronto time).

Mandalay Resources Corporation (MNDJF), closed Tuesday's trading session at $1.3829, off by 4.6276%, on 16,223 volume with 36 trades. The average volume for the last 3 months is 10,575 and the stock's 52-week low/high is $0.382099986/$1.64999997.

chart

Recruiter.com Group, Inc. (RCRT)

Zacks, Wallet Investor, Penny Stock Hub, Last10k, TradingView, OTC Markets, GlobeNewswire, Nasdaq, Investors Hangout, Stockopedia, Dividend Investor, GuruFocus, InvestorsHub, Dividend.com, Stockhouse, MacroTrends, Investor Ideas, Market Wire News, and TipRanks reported earlier on Recruiter.com Group, Inc. (RCRT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Recruiter.com Group, Inc. is a leading platform connecting recruiters and employers. An expert network for recruiters, the Company pairs enterprises with an extensive network of recruiters and powerful AI (Artificial Intelligence) matching tools to foster the hiring of premier talent faster and smarter. Recruiter.com provides recruiters SHRM certified recruitment training and independent earning opportunity. It provides enterprise and mid-market employers recruiting services designed to scale across a varied range of skills and industries.

Recruiter.com Group is headquartered in Houston, Texas. The Company also has additional offices in Bristol, Connecticut, and Ebene, Mauritius. Recruiter.com Group lists on the OTC Markets Group’s OTCQB.

The Company has strategic partnerships in manifold areas of the recruitment process. These include AI candidate matching software, applicant tracking systems, job sites, resume writing and career services, recruitment and career content providers, and recruitment service and outsourcing firms.

The design of Recruiter.com’s business is to accelerate recruiting and hiring success by way of technology adoption. The Company’s chief product and service is its cloud-based “Job Market” software platform for professional hiring. The Job Market software facilitates connections to a nationwide network of professional recruiters.

Furthermore, the Job Market software is augmented by proprietary AI technologies that draw from talent communities of millions of people. Recruiter.com provides employers a flexible, performance-based hiring model for permanent and contract talent. Recruiter.com Group has a strategic partnership agreement with Censia, Inc. Censia is the operator of a worldwide talent intelligence platform with half a billion of the world’s professionals, indexed and analyzed through AI. This partnership with Censia enables Recruiter.com’s network of independent recruiters and internal Talent Delivery team access to Censia on a performance basis.

This past February, Recruiter.com announced the launch of its Recruiters on Demand solution offering. The Recruiters on Demand program is a flexible, monthly solution to easily add recruiters to a team without the commitment of hiring full-time staff recruiters. Employers can use the program to scale their internal talent acquisition teams on an as-required basis through hiring independent recruiters from Recruiter.com. Recruiters on Demand provides Human Resources departments and recruitment teams the opportunity to hire recruiters either virtually or on-site on location.

Last week, Recruiter.com announced a partnership with DVBE Connect to build a curated on-demand team of veteran recruiters. DVBE is an award-winning, disabled veteran-owned recruiting and staffing enterprise. Recruiter.com enables any employer to easily add recruiters to their talent acquisition team to get them through a period of fast-growth and hiring, with simple, flat monthly pricing and no success fees.

Recruiter.com Group, Inc. (RCRT), closed Tuesday's trading session at $2.15, off by 2.2727%, on 1,600 volume with 4 trades. The average volume for the last 3 months is 3,998 and the stock's 52-week low/high is $0.560000002/$4.99989986.

chart

WildBrain Ltd. (WLDBF)

OTC Markets, Market Screener, Dividend Investor, FX Empire, Morningstar, GuruFocus, Dividend.com, PR Newswire, Newsday, Ask Finny, Newswire.ca, ETFChannel.com, MarketBeat, News Break, Stockhouse, Nasdaq, TradingView, Analyst Ratings, MarketWatch, Seeking Alpha, Barchart, and Street Insider reported beforehand on WildBrain Ltd. (WLDBF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

WildBrain Ltd. is a global leader in kids and family entertainment. The Company has approximately 13,000 half-hours of filmed entertainment in its library. Its shows are seen in more than 150 countries on over 500 telecasters and streaming platforms. The Company was formerly known as DHX Media Ltd. It changed its corporate name to WildBrain Ltd. in December of 2019. Incorporated in 2004, WildBrain is based in Halifax, Nova Scotia and also has offices internationally. WildBrain’s distribution team is in Toronto, Paris, and Beijing.

WildBrain is home to brands including Peanuts, Teletubbies, Strawberry Shortcake, Caillou, Inspector Gadget, Johnny Test, and Degrassi. The Company’s AVOD business - WildBrain Spark - offers one of the largest networks of kids' channels on YouTube, with greater than 168 million subscribers. WildBrain Spark builds brands through the management and creation of preschool and children’s entertainment content on platforms including YouTube, Amazon Video Direct, and ROKU.

WildBrain also licenses consumer products and location-based entertainment in every major territory for its own properties and for its clients and content partners. The Company’s television group owns and operates four family entertainment channels that are among the most viewed in Canada. WildBrain Studios works with international partners including Apple, Netflix, LEGO, DreamWorks, BBC, Cartoon Network, Nickelodeon and more. It develops and produces original animated and live-action series for audiences from preschoolers to teens.

WildBrain Television comprises Family Channel, Family CHRGD, Family Jr., and Télémagino. WildBrain Television is home to world-renowned series. These include America Ninja Warrior Jr., Miraculous: Tales of Ladybug and Cat Noir, Just Add Magic, and Chip and Potato.

This past June, WildBrain announced that it completed the Initial Closing of a US$12.2 Million financing for growth initiatives. The funds are reserved for acquisitions and investments to propel WildBrain's content and brand strategy, with a special emphasis on its AVOD business, WildBrain Spark.

Mr. Eric Ellenbogen, Chief Executive Officer of WildBrain, said, "One of the most exciting growth opportunities in the media industry is the rise of AVOD. This capital will allow us to finance accretive investments across areas such as content, IP, and technology, especially in our AVOD business, WildBrain Spark. With four billion monthly views across over 800 channels, WildBrain Spark attracts one of the largest and most engaged global audiences in the kids and family space. We see it as a key driver of IP for our business."

WildBrain Ltd. (WLDBF), closed Tuesday's trading session at $0.9164, off by 4.3074%, on 2,637 volume with 10 trades. The average volume for the last 3 months is 41,389 and the stock's 52-week low/high is $0.480100005/$1.75020003.

chart

American Battery Metals Corporation (ABML)

OTC Markets, Stockwatch, Real Investment Advice, TipRanks, Newsfilecorp, WasteAdvantageMag, Penny Stock Hub, Mining Stock Education, Investing News, Proactive Investors, Investor Place, Digital Journal, Business Insider, Stockhouse, Investment Pitch, YCharts, Mining Journal, Investing.com, Wallet Investor, Simply Wall St, Big News Network, Mining.com, Mining Capital, and Investors Hangout reported earlier on American Battery Metals Corporation (ABML), and today we report on the Company, here at the QualityStocks Daily Newsletter.

American Battery Metals Corporation is a premier battery metal exploration and development company. Its emphasis is on its Railroad Valley battery metal project in Nevada with the aim of becoming a major domestic supplier of battery metals to the growing electric vehicles (EV) and battery storage markets in the United States. The Company previously went by the name Oroplata Resources, Inc. It changed its name to American Battery Metals Corporation in May of 2019. Incorporated in 2011 and OTCQB-listed, American Battery Metals is based in Incline Village, Nevada.

American Battery Metals, via its subsidiaries, engages in the exploration and development of lithium properties. It announced in July of 2019 that results of its first geophysical exploration program demonstrate that a large and undefined reservoir exists on its property in Railroad Valley, Nevada. The geophysical Magnetotelluric (MT) Survey was conducted over a square mile area by Zonge International of Reno, Nevada. Zonge has extensive experience in geophysical data acquisition and target identification on Lithium Exploration Projects.

The results of the geophysical survey indicate two large conductive zones located within the project area. "Conductive Zones" could indicate the presence of Lithium concentration in shallow clay deposits and in deeper Brine deposits. One of these conductive zones was earlier drill tested to a depth of 3,000 feet.

At present, the Company has mining claims on 26,000 acres in the area called the Western Nevada Basin, in Railroad Valley in Nye County, Nevada (WNB Claim). In the second half of 2017, American Battery Metals engaged experts to evaluate the area and the WNB Claim to target on-site exploration efforts. It determined that 260 claims of the WNB Claim were appropriate for its planned exploration that started in April 2019.

American Battery Metals Corporation recently announced its intention to change its corporate name to American Battery Technology Company. This is to better reflect its principal focus and mission. Over the past number of months, the Company has readied and positioned itself for its planned lithium-ion battery metals recycling plant in Nevada, with many new hires, including a number from Tesla.

Last month, American Battery Metals announced that it entered an escrow to purchase roughly 12½ acres of industrial land in Fernley, Nevada, where it anticipates locating its first-of-its-kind lithium-ion battery recycling facility. The industrial space is in a Qualified Opportunity Zone (QOZ) in northern Nevada. The Opportunity Zone Tax Incentive was created to encourage private investment of capital into projects, businesses, as well as property development in northern Nevada.

Last week, American Battery Metals announced that its Chief Technology Officer (CTO), Mr. Ryan Melsert was recently interviewed by Mr. Steve Darling of Proactive Investors. The interview centered on American Battery Metals’ purchase of a piece of property in Nevada and its construction and implementation plans for its lithium-ion battery metals recycling plant.

American Battery Metals Chief Executive Officer, Mr. Doug Cole, stated, "We are 100 percent focused in getting this plant operational. We recently completed the initial construction financing necessary to build out the plant. We are in final stages of discussion of the permanent take-out financing with several long-term partners, one of which is the SBA to finance the completed plant."

American Battery Metals Corporation (ABML), closed Tuesday's trading session at $0.1029, off by 0.097087%, on 1,043,462 volume with 142 trades. The average volume for the last 3 months is 2,820,000 and the stock's 52-week low/high is $0.02438/$0.180000007.

chart

Benchmark Metals, Inc. (CYRTF)

Stock Day Media, StocksCafe, Mining Capital, Resource World, Junior Mining Network, OTC Markets, MarketWatch, Morningstar, Stockhouse, TradingView, Dividend.com, Barchart, Nasdaq, Seeking Alpha, Streetwise Reports, Market Screener, GreenShoeMedia, Newsfilecorp, TMXmoney, GuruFocus, FX Empire, Proactive Investors, and Simply Wall St reported earlier on Benchmark Metals, Inc. (CYRTF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Benchmark Metals, Inc. focuses on proving and developing the considerable resource potential of the Lawyer's Gold-Silver Project, situated in the prolific Golden Horseshoe of northern British Columbia. The Company is part of the Metals Group portfolio of companies. The OTCQB-listed Company formerly went by the name Crystal Exploration, Inc. It changed its name to Benchmark Metals, Inc. in May of 2018. Incorporated in 2010, Benchmark Metals has its head office in Edmonton, Alberta.

Proven resource sector professionals, who have a record of accomplishment of advancing exploration projects from grassroots scenarios through to production, manage Benchmark Metals. The Lawyers Property encompasses 140 km2 of highly prospective rocks in the northeastern region of the prolific metal-endowed Stikine Terrane, British Columbia.

The Lawyers Project spans an important stratigraphic horizon between rocks of the Upper Triassic Stuhini Group and Lower Jurassic Hazelton Group, which define an important geological unconformity with many of the deposits in the Golden Horseshoe concentrated along it. In addition, the project is positioned in a proven and profitable mining jurisdiction, only 45 km northwest of the Kemess gold-copper mine. At the heart of the Laywers Trend is the structurally controlled Cliff Creek, Dukes Ridge, Phoenix, and AGB zones situated within a large 5 km by 8 km radiometric anomaly that is coincident with potassic alteration, associated with a low-sulphidation epithermal system.

In July, Benchmark Metals announced that it added a fifth drill rig to its 50,000 meter drill program at the Lawyers Project and provided an update on the drilling and field exploration completed to date. More than 10,500 meters has been completed from 60-plus drill holes targeting resource definition and expansion areas. Sample shipments to the laboratory are continuing.

All 2020 drilling to date is centered on defining and expanding a mineral resource from three key areas: the Cliff Creek Zone, the Dukes Ridge to Phoenix Zones, and the AGB Zone. Field work has been effective at advancing new drill targets for potential new discoveries at the Silver Pond Porphyry target and the Marmot Zone.

Last week, Benchmark Metals announced results from drill-hole 20CCRC003 that intersected, from surface, broad mineralization that yielded 57.91 meters (m) of 1.90 grams per tonne (g/t) gold and 91.96 g/t silver or 3.05 g/t gold equivalent (AuEq). Within this mineralized envelope higher-grade intervals include 33.53 meters of 3.17 g/t gold and 152.28 g/t silver or 5.07 g/t AuEq. This result is the first assays received from more than 20,000 completed meters from 117 holes as part of the Company’s planned 50,000 meter drill program.

Benchmark Metals, Inc. (CYRTF), closed Tuesday's trading session at $1.12, off by 7.188%, on 144,429 volume with 121 trades. The average volume for the last 3 months is 91,217 and the stock's 52-week low/high is $0.119999997/$1.21941995.

chart

BrainsWay Ltd. (BWAY)

Zacks, OTC Markets, Barchart, InvestorsHub, Whale Wisdom, Research and Markets, TipRanks, Webull, Simply Wall St, Business Insider, TradingView, Stocknews, Stocktwits, Market Screener, Street Insider, Stockhouse, YCharts, ChartMill, Seeking Alpha, Investing.com, Finbox, Market Chameleon, MacroTrends, MarketBeat, TMXmoney, Morningstar, Finviz, MarketWatch, Nasdaq, and GlobeNewswire reported earlier on BrainsWay Ltd. (BWAY), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

BrainsWay Ltd. is an international leader in the advanced non-invasive treatment of brain disorders. A commercial stage medical device enterprise, it concentrates on the development and sale of non-invasive neuromodulation products using its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Company mainly serves doctors, hospitals, as well as medical centers in the field of psychiatry. BrainsWay lists on the NasdaqGS.

BrainsWay received marketing authorization from the U.S. Food and Drug Administration (FDA) in 2013 for MDD and in 2018 for OCD. At present, the Company is conducting clinical trials of Deep TMS in diverse psychiatric, neurological, and addiction disorders. BrainsWay’s treatment is based on patents filed jointly by the Company and the U.S. National Institutes of Health (NIH), and held exclusively by BrainsWay.

BrainsWay holds CE Mark clearance outside of North America for manifold additional psychiatric and neurological conditions. This includes Post-Traumatic Stress Disorder (PTSD) and Alzheimer’s Disease (AD). In addition, the Company is approved in Canada for the treatment of Major Depressive Disorder (Health Canada Licence No. 90504).

BrainsWay collaborates with top scientists and academic research institutions globally in clinical trials covering different neuropsychiatric and neuroscience applications. The Company’s Deep transcranial magnetic stimulation (dTMS), is a non-invasive treatment process that directly stimulates brain structures associated with mental health conditions. This is done using electromagnetic fields generated by BrainsWay’s patented H-coil to safely reach deeper brain structures and influence their neural activity.

Deep TMS administers magnetic waves via a cushioned helmet to target deep structures of the brain that impact a patients’ depression and OCD symptoms. BrainsWay has been treating depression with Deep TMS for over 10 years.

In July, BrainsWay announced that University TMS, a mental health facility specializing in advanced treatments for neurological and psychiatric disorders, is now offering BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) for major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). University TMS provides comprehensive treatments to effectively treat depression, addiction, and other brain disorders with non-surgical treatments, such as Deep TMS.

Dr. Timothy Prestley, M.D., Founder and neurologist at University TMS, said “Our mission is to provide hope through innovative and noninvasive treatment options, such as Deep TMS. Many mental illnesses, including depression and OCD, have been exacerbated during the COVID-19 pandemic, and we want to have every tool in our belt to help those living in the Tuscaloosa County community.”

BrainsWay will report its Q2 2020 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 12, 2020. BrainsWay will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

BrainsWay Ltd. (BWAY), closed Tuesday's trading session at $6.27, up 2.9557%, on 11,644 volume with 102 trades. The average volume for the last 3 months is 5,859 and the stock's 52-week low/high is $5.0999999/$12.5299997.

chart

Acacia Pharma Group plc (ACPGF)

Zacks, Stock Day Media, Stock Scores, Investors News, Real Investment Advice, Market Wire News, Tech Know Bits, Simply Wall St, Stockaholics, Financial Insiders, OTC.Watch, Stockwatch, Emerging Growth, Stock Target Advisor, Financial Buzz, Research Pool,Investing.com, Wallet Investor, and MarketBeat reported earlier on Acacia Pharma Group plc (ACPGF), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Acacia Pharma Group plc is a hospital pharmaceutical group focusing on the development and commercialization of new nausea and vomiting treatments for surgical and cancer patients. The Company has developed a late-stage pipeline of hospital nausea and vomiting product candidates based on repurposing existing drugs in new therapeutic indications. Its product candidates are differentiated from the original marketed drug by using a different delivery method and/or dose that is suitable for its new medical use. Acacia Pharma Group is headquartered in Cambridge, the United Kingdom (UK). The Company’s U.S. operations are centered in Indianapolis, Indiana.

Acacia Pharma has discovered two product candidates based on the same active ingredient, amisulpride. BARHEMSYS® (previously APD421) is an intravenous formulation of amisulpride, a selective dopamine antagonist that has completed Phase 3 clinical development for the prophylaxis and treatment of post-operative nausea & vomiting (PONV), alone and in combination with other antiemetics.

APD403 is based on the selective dopamine antagonist amisulpride, the same active ingredient as in BARHEMSYS®. It is undergoing development as an intravenous injection for cancer patients to be administered immediately before they receive chemotherapy to prevent acute chemotherapy-induced nausea & vomiting (CINV), and as an oral tablet to prevent delayed CINV.

This past January, Acacia Pharma announced that it entered into a strategic in-licensing transaction with Cosmo Pharmaceuticals N.V. (SIX: COPN). The transaction grants to the Group exclusive U.S. commercialization rights to ByFavo™ (remimazolam). It has been made alongside an equity investment and debt facility by Cosmo Pharmaceuticals to finance the marketing efforts of BARHEMSYS® and ByFavo™.

ByFavo™ is an ultra-short-acting and reversible intravenous sedative/anaesthetic. BYFAVO has demonstrated efficacy and safety in an extensive clinical trial programme involving roughly 2,400 volunteers and patients. Data so far indicates that remimazolam has a fast onset and offset of action combined with a good cardio-respiratory safety profile.

The FDA (Food and Drug Administration) has extended the review period for the New Drug Application (NDA) for BYFAVO™ (remimazolam) by up to 90 days so as to complete its review of additional data submitted in January and February 2020. The FDA set a new Prescription Drug User Fee Act (PDUFA) goal of reviewing and acting on the NDA of no later than July 5, 2020 (previous PDUFA target date was April 5, 2020). Cosmo Pharmaceuticals in-licensed the US rights to BYFAVO from Paion AG in 2016 and together they have progressed the product candidate through to registration.

Acacia Pharma Group plc (ACPGF), closed Tuesday's trading session at $5.00, up 53.8462%, on 500 volume with 1 trade. The stock's 52-week low/high is $2.45000004/$5.00.

chart

Jupiter Gold Corporation (JUPGF)

OTC Markets, Barchart, OTC Dynamics, AskTraders, Stockopedia, Dividend Investor, GlobeNewswire, Dividend.com, and Stockhouse reported earlier on Jupiter Gold Corporation (JUPGF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Jupiter Gold Corporation is focused on gold assets in Brazil. It owns 100 percent title to seven gold projects in development and exploratory stages aggregating 125,000 acres in Brazil. The Company has acreage in some of the best gold Provinces in Brazil. Brazil Minerals, Inc. (BMIX) owns 39 percent of the outstanding shares of Jupiter Gold. Based in Brazil, Jupiter Gold lists on the OTC Markets.

The Company is a project generator. Its plan is to use capital carefully and it will mine areas where operations are simpler, and JV/partner/transact other projects. All of Jupiter Gold’s project locations are strategically chosen after a multi-factorial proprietary evaluation (geological, environmental, logistical). The Company states that proof of its successful approach is the Paracatu Project - chosen as a greenfield project after Jupiter Gold’s analytical assessment, and its gold mineralization later confirmed by detailed drilling.

Jupiter Gold has its Paracatu, Crixás, Serrita, Apuí, Itabira, and Diamantina Projects. Paracatu is 795 acres; Crixás is 4,925 acres; Serrita is 14,169 acres; Apuí is 69,030 acres; Itabira is 4,069 acres; and Diamantina is 4,970 acres. Jupiter Gold 100 percent owns all of these Projects.

Moreover, in November, Jupiter Gold announced that it started the confirmatory field work to revalidate the reported 64,000 ounces of gold mineralization in its recently announced project in Brazil, referred to as “Alpha Project”. The initial field work at the Company’s Alpha Project included careful analysis of all observed sites where previous trenching and drilling was done in the period from the late 1990’s to 2004 by a prior owner. In particular, a specialized field geologist descended 70 feet and 60 feet in two shafts, each separated 60 feet from the other. On the walls of both shafts, quartz with veins consistent with potential for primary gold was observed.

The previous owners of the Alpha Project pursued detailed geological trenching and drilling. Their official report filed with the Brazilian mining authorities quantified 64,000 ounces of potential gold mineralization with an average of 1.54 g/t of gold in the area studied.

Recently, Jupiter Gold announced that the results of the geochemical sampling conducted in two shafts (70 ft. and 60 ft. deep, spaced 60 ft.) in its Alpha Project included a 16.2 g/t gold intersect within a 5.0 g/t gold zone over 4 meters. In terms of detection, 36 out of the 37 samples returned positive for gold. The analytical test used was fire assay (FAA505) performed by SGS-Geosol, a first-rate laboratory used by major mining companies in Brazil.

Given these positive results, Jupiter Gold plans to advance on more studies, which may lead to a technical report (NI 43-101 or equivalent format) for the property. In parallel, the Company has commenced the planning of the regulatory studies required for an initial gold production license.

Jupiter Gold Corporation (JUPGF), closed Tuesday's trading session at $1.50, up 41.5094%, on 1,277 volume with 5 trades. The average volume for the last 3 months is 237 and the stock's 52-week low/high is $0.200000002/$1.75.

chart

XT Energy Group, Inc. (XTEG)

Penny Stock Hub, Zacks, OTC Markets, Wallstreet Online, Investors Hangout, MarketScreener, Last10k, StreetInsider, Stock Target Advisor, Investing.com, WhaleWisdom, GuruFocus, TradingView, Wallet Investor, Simply Wall St, MarketWatch, and YCharts reported previously on XT Energy Group, Inc. (XTEG), and today we report on the Company, here at the QualityStocks Daily Newsletter.

XT Energy Group, Inc. provides renewable energy services. It centers on the development of electricity generation systems, installation of photovoltaic solar panels, as well as related products. XT Energy Group serves customers in the People’s Republic of China (PRC) and in the United States. The Company’s shares trade on the OTC Markets Group’s OTCQB. The Company previously went by the name Xiangtian (USA) Air Power Co., Ltd. It changed its name to XT Energy Group, Inc. in November of last year. Established in 2008 by Deng Rong Zhou, XT Energy Group has its corporate headquarters in Xianning, Hubei Province, China.

XT Energy Group engages in the compressed air energy storage field, chiefly in the PRC. XT Energy offers air compression power generation systems with a photovoltaic (PV) installation for industrial users, including factories and power plants; and PV systems without the air compression generation technology. XT Energy engages in the production of electricity generation systems, which combines the compressed air storage technology with photovoltaic panels of the Company. Furthermore, XT employs proprietary compressed air energy storage power generation technology that can store energy for other alternative energy sources such as using solar, wind, geothermal, and tidal as raw power to regenerate electricity power without the use of fossil fuels or other chemical methods.

In addition, the Company provides air source heat pump systems that transfers heat from outside to inside of a building, or vice versa; PV panels; synthetic fuel and related products, such as fuel additives, engine lubricants, and methanol fuel. XT Energy also provides hydraulic parts consisting of hydraulic cylinders, diesel pumps, motor oil pumps, and hydraulic valves. Moreover, XT Energy designs and manufactures hydraulic pump stations, cylinders, and also high-pressure valves.

In essence, XT Energy Group is a holding company primarily engaged in energy-related businesses. The Company is involved in the installation of power generation systems by way of its subsidiaries and controlled entities.

XT Energy Group, Inc. (XTEG), closed Tuesday's trading session at $0.2375, up 216.6667%, on 2,000 volume with 2 trades. The average volume for the last 3 months is 1,906 and the stock's 52-week low/high is $0.035/$4.1999998.

chart

Lamperd Less Lethal, Inc. (LLLI)

Silicon Investor, Penny Stock Tweets, Investor Village, Equity Clock, Front Page Stocks, Last10k, and Stockopedia reported earlier on Lamperd Less Lethal, Inc. (LLLI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Lamperd Less Lethal, Inc. designs, develops, manufactures, and sells civil and military defense equipment globally. The Company is an innovation leader and manufacturer of advanced security solutions for law enforcement, military and security agencies around the world. In addition, Lamperd offers advisory services and hands-on training classes run by highly accredited instructors. Lamperd Less Lethal is based in Sarnia, Ontario. The Company lists on the OTC Markets.

The Company sells more than 300 different products. These include small and large caliber projectile guns, flash-bang devices, pepper spray devices, 37mm & 40mm launching systems, and interlocking riot shields. Lamperd provides less lethal solutions to keep situations under control.

Lamperd Less Lethal offers a premier range of force training products and aids. The design of each is to maximize the training experience and bring realism to the process. Lamperd offers Training Aids, Law Enforcement Aids, as well as Shield Systems. The design of Lamperd Shields are to augment unit strength and ability via the innovative interlocking system incorporated into each shield.

Lamperd’s Extraction Shield is specifically designed for police officers or other emergency personnel who must deal with violent or unstable persons, including accident victims. This device is ideally sized and shaped to prevent broken ribs and other common injuries or bodily fluid contamination while transferring such persons to and from police cars, ambulances or other tight spaces.

Regarding Less Lethal Munitions, the Company offers 20 gauge, 12 gauge, 9 mm, 50 cal, 37- 40 mm. The design of all munitions are to fit standard issue magazines and standard weaponry, including pistols, rifles, shotguns, and launchers.

Concerning Less Lethal Solutions, Lamperd created a first-rate line of Less Lethal firearms/delivery systems and munitions ranging from 9mm to 50 caliber and impact rounds from 37 to 40 MM. The Company has its Defender I. It is a five shot, compact, lightweight hand held revolver delivering 20-Gauge incapacitating projectiles. Defender I is the only Less Lethal Delivery System that allows officers Instant Round Identification in critical situations.

Lamperd Less Lethal also has its Defender II. It is a shoulder fired, 20 Gauge Less Lethal delivery system. It operates on the time tested 5 round revolver action. The gun has an 18 ¾ inch barrel that is very accurate. It serves it very well for long distant shots for public order. Defender II is compact enough to be deployed in Close Quarter Battle situations.

This past April, Lamperd Less Lethal announced that it received a signed purchase order for guns and ammunition from an important new international police services customer. The value of the initial order for Lamperd products is totaled at $172,000 USD. This represents the largest international order that Lamperd has received to date (as of April 2, 2019).

Recently, Lamperd Less Lethal announced that it welcomed its latest distribution partner that will represent the full Lamperd product line. This new partner has wide-ranging experience in the security products field and excellent established client base contacts. LTL Global, LLC, headquartered in Southern Florida, offers advanced less than lethal security options globally. It has been manufacturing and selling its own line of 37mm launcher products for many years.

Starting immediately, LTL Global is authorized to sell the full Lamperd Less Lethal product line to buyers in any part of the U.S. Furthermore, LTL Global will now have an exclusive arrangement to market the Lamperd Less Lethal line to buyers in Latin America, which is a territory where LTL Global has had substantial experience and many professional contacts in the law enforcement and military fields.

Lamperd Less Lethal, Inc. (LLLI), closed Tuesday's trading session at $0.029, up 81.25%, on 11,501,035 volume with 444 trades. The average volume for the last 3 months is 884,100 and the stock's 52-week low/high is $0.004999999/$0.0291.

chart

Predictive Technology Group, Inc. (PRED)

NetworkNewsWire, Zacks, InvestorsHub, Insider Financial, Wallet Investor, Stockhouse, Wallmine, Infront Analytics, The Street, StreetWise Reports, Dividend Investor, and Simply Wall St reported earlier on Predictive Technology Group, Inc. (PRED), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Predictive Technology Group, Inc. is a therapeutics and life sciences company headquartered in Salt Lake City, Utah. It is a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through inventive novel gene-based diagnostics, biotechnology treatments and companion therapeutics. The Company formerly went by the name Global Enterprises Group, Inc. It changed its name to Predictive Technology Group, Inc. in July 2015. Predictive Technology Group lists on the OTC Markets.

The Company’s wholly-owned subsidiaries are Predictive Therapeutics and Predictive Biotech. Through these, it focuses on four primary clinical categories. These are Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Human Cell and Tissue Products. Predictive Laboratories concentrates on clinical and discovery work for human infertility and genetic conditions affecting women and children. Testing is performed using state-of-the-art instrumentation at its CAP and CLIA accredited facility.

Further to Predictive Biotech’s efforts to advance regenerative medicine, Predictive Therapeutics’ dedication is to assisting women in overcoming the devastating consequences of endometriosis through appropriate early-stage diagnosis and subsequent treatment. Subsidiary Predictive Biotech is a leader in human cell and tissue products for use in regenerative medicine. A growing national network of clinics, health systems, researchers and physicians take advantage of Predictive Biotech’s four main placental-derived and Wharton’s jelly umbilical cord-derived products (AmnioCyte™, AmnioCyte Plus™, PolyCyte™, CoreCyte™).

Predictive Technology Group recently announced that its wholly-owned subsidiary, Predictive Laboratories, reached an enrollment milestone of 200 participants in its ongoing Institutional Review Board (IRB)-approved study of spine and joint disease leading to chronic pain. Predictive Laboratories is the sponsor of the study. Kenneth Ward, MD, Laboratory Director of Predictive Laboratories, serves as Principal Investigator.

The primary objective of the IRB study is to conduct genetic research related to healthcare advancement in the diagnosis, treatment and prevention of conditions causing chronic pain. The first 200 participants have volunteered for the study by submitting their DNA samples to the Predictive Biorepository and by reporting detailed medical information through their healthcare providers.

Predictive Technology previously announced the signing of a letter of intent (LOI) with IQVIA (Formerly Quintiles and IMS) to guide the regulatory strategy for its wholly-owned subsidiary Predictive Biotech. The collaboration will expedite the process of identifying and executing the appropriate regulatory pathways for the Company’s existing products and future product candidates.

Recently, Predictive Technology Group announced that Douglas S. Rabin, MD, has joined Predictive Laboratories as Vice President of Medical Affairs, Women’s Health. In this newly created position, Dr. Rabin will provide critical medical affairs support for the women's health clinical franchise. He has over 25 years of experience in women's healthcare. This includes clinical reproductive endocrinology, and obstetrics and gynecology.

Mr. Bradley Robinson, Predictive Technology Group Chief Executive Officer, said, “We welcome Dr. Rabin to the Predictive team to support our goal of commercializing our innovative, genetic-based diagnostics that are initially focus on human infertility and women’s health. Dr. Rabin is highly accomplished in launching pharmaceutical and diagnostic products at Fortune 500 companies. His experience and commitment to delivering improved, more comprehensive healthcare to patients will be of tremendous assistance in supporting our mission of employing advanced molecular diagnostics to prevent or eliminate disease for generations to come.”

Predictive Technology Group, Inc. (PRED), closed Tuesday's trading session at $0.29, up 45.00%, on 117,533 volume with 32 trades. The average volume for the last 3 months is 223,643 and the stock's 52-week low/high is $0.368750005/$6.90999984.

chart

Digerati Technologies, Inc. (DTGI)

Emerging Growth, Zacks, MarketWatch, Stockhouse, Real Investment Advice, OTCPicks, AllPennyStocks, GuruFocus, MicrocapVoice, Equities, Marketwired, SmallCapVoice, The Street, InvestorsHub, Stockopedia, Wallet Investor, and Morningstar reported earlier on Digerati Technologies, Inc. (DTGI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Digerati Technologies, Inc. is a diversified holding company listed on the OTC Markets’ OTCQB. It has subsidiary operations in the cloud communications industry. The Company, via its  wholly-owned  subsidiary, Shift8 Technologies, Inc., provides Internet-based telephony products and services through its cloud telephony application platform and session-based communication network. is headquartered in San Antonio, Texas.

Fundamentally, the Company is an established and award-winning provider of cloud communication services. It serves traditional carriers, telephony resellers, as well as other VoIP  (Voice over Internet Protocol) carriers in the United States and worldwide. Digerati Technologies provides VoIP communication services to telecommunications companies.

Digerati Technologies completed the acquisition of Synergy Telecom, Inc. in 2017. Digerati’s Shift8 Networks combined Synergy Telecom with its Texas-based business and operations. Synergy Telecom is a foremost provider of cloud communication services in Texas.

In 2018, Digerati Technologies completed the acquisition of T3 Communications, Inc. It stated that this acquisition positions Digerati for hyper-growth in two of the fastest growing sectors of the telecommunications industry, UCaaS (Unified Communications as a Service) and SD-WAN (Software-Defined Wide-Area Network). T3 Communications is a top provider of cloud communications and broadband solutions in Southwest Florida.

Digerati’s Shift8 Networks subsidiary is an enterprise hosted PBX and cloud-based Unified Communications service provider. Shift8 Networks provides voice, video, and mobile communications to thousands of businesses via its Channel Alliance program.

Shift8 integrates hosted VoIP with cloud-based messaging and desktop applications. Its VAR program targets PBX Vendors, Information Technology (IT) Services firms, Managed Service Providers, and Systems Integrators that lack a cloud telephony infrastructure, but have an embedded customer base that needs Internet-based telephony services.

Digerati also provides Internet-based services. These include  fully hosted IP/PBX services, IP trunking; call center applications, prepaid services, and interactive voice response auto attendant. Services additionally include call recording, simultaneous calling, voicemail to email conversion, and many customized IP/PBX features in a hosted or cloud environment for specialized applications.

Digerati has launched a mobile ‘business continuity’ solution in partnership with Otarris, a division of Kajeet, Inc., for addressing the increasing demand for disaster recovery networks in the enterprise marketplace. Digerati is addressing the growing need for its customers to deploy a redundant and diverse bandwidth solution for ‘business continuity’ during primary network outages. These include those caused by natural or human-induced disasters.

Recently, Digerati Technologies announced that it entered into an agreement to acquire a minority ownership stake in Itellum Comunicaciones Costa Rica S.R.L. Itellum is a fully licensed telecommunication and Internet Service Provider. With this agreement, Digerati expands its long-standing relationship with Itellum, a regional Partner and VAR (Value-Added Reseller) for its cloud communication services. Digerati's purchase of a minority stake secures Itellum as the exclusive provider of Digerati's services. It also positions Digerati Technologies to better serve Central America.

Digerati Technologies, Inc. (DTGI), closed Tuesday's trading session at $0.0585, up 63.6364%, on 7,329,473 volume with 415 trades. The average volume for the last 3 months is 997,126 and the stock's 52-week low/high is $0.0109/$0.180099993.

chart

Sunvalley Solar, Inc. (SSOL)

Wallstreetlivechat, PennyStockPros, The Stock Scout, Penny Stock Rumble, Stockhunter.us, PennyStockClub, OurHotStockPicks, PennyStocks24, Fast Moving Stocks, VIP STOCK ALERTS, and FeedBlitz reported previously on Sunvalley Solar, Inc. (SSOL), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Sunvalley Solar, Inc., by way of its subsidiary, Sunvalley Solar Tech, Inc., operates as a solar power technology and system integration company in the State of California. The Company centers on solar systems design and installation, solar technology research and development (R&D), and solar equipment manufacturing and distribution areas. Established in 2007, Sunvalley Solar is headquartered in in Walnut, California.

Sunvalley Solar acquired Rayco Energy, Inc. in 2016. Rayco Energy is an established northern California company. It specializes in providing cost-saving and efficient energy solutions to local communities and business units. This includes LED lighting, Solar Thermal, as well as Solar Electricity.

Rayco Energy combines energy efficiency measures with renewable energy sources. It services the multi-family sector (Apartments, Homeowner Associations (HOA)) and small-sized commercial projects.

Sunvalley Solar’s business development strategy is to develop the Company as the end-to-end solar energy solution provider for solar power equipment dealers, solar power system installers, and solar power energy end users.

The Company provides turnkey solar system solutions. These include designing, building, operating, monitoring, and maintaining solar power systems for owners, builders, and architecture firms. Its R&D team comprises PhDs in Optoelectronics. The team specializes in photovoltaic panel technologies (coating and focusing).

In addition, the Company’s focus is in the area of National Solar Technical Support and a Service Center. Sunvalley Solar serves small private residences and large commercial solar power users.

The Company’s R&D team’s projects include 975 kW commercial solar power systems for distribution warehouses and manufacturing companies. Furthermore, projects include 1 MW commercial solar power systems for agriculture farms and cold storage facilities.

Its R&D is presently focusing on developing new coating technology to increase the efficiency of PV panels; developing new focusing technology to reduce the size of silicon cells and reduce the silicon cost per watt; developing solar PV application technology to decrease system level cost; and developing new solar parts – Micro-inverters.

Sunvalley Solar has its patented technology – Networked Solar Panels and Related Methods. It has patented the technology "Networked Solar Panels and Related Methods" (USPTO 12/198,076). This technology enables the solar power system operator to monitor the grid status, and manage and control the output from each panel, each subsystem, and the system as a whole.

Sunvalley Solar, Inc. (SSOL), closed Tuesday's trading session at $0.10, up 42.6534%, on 4,703 volume with 8 trades. The average volume for the last 3 months is 11,593 and the stock's 52-week low/high is $0.012699999/$0.1937.

chart

The QualityStocks Company Corner

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX Inc. (NASDAQ: SRAX), a digital marketing pioneer focused on providing consumer data management services, has announced the launch of a new payment system for its proprietary BIGtoken platform. Through its revolutionary BIGtoken platform, which boasted 16.7 million users as of the end of the first quarter of 2020, SRAX enables its subscribers to provide their advertisers with access to verified consumer data, which in turn can help companies better reach and serve their audiences. Now, as a part of its new initiative to continue growing out its platform, SRAX has announced the launch of BIG Seasons – a new payment system for the millions of subscribers on its platform (http://nnw.fm/AMOCN).

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Tuesday's trading session at $2.90, up 5.0725%, on 201,971 volume with 528 trades. The average volume for the last 3 months is 76,228 and the stock's 52-week low/high is $1.04999995/$3.74.

Recent News

chart

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

Mullen Technologies ("Mullen" or the "Company"), an emerging electric vehicle ("EV") manufacturer and technology company, which previously announced a definitive agreement to merge with Net Element (NASDAQ: NETE) in a stock-for-stock reverse merger, today announced that the Company will present at the J.P. Morgan Virtual Auto Conference. To view the full press release, visit http://ibn.fm/dWX2S. Also today, NetworkNewsWire released a report on the company detailing how, since 2013, the sale of electric vehicles (EV) in the United States has grown by an average of 25% a year (http://nnw.fm/B2GRb), a stunning figure when compared to the anemic 1.4% overall growth of the US auto market over the same interim (http://nnw.fm/hwjS2). 

On June 15, 2020, Net Element announced its entry into a binding letter of intent to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company, in a stock-for-stock reverse merger in which Mullen’s stockholders will receive the majority of the outstanding stock in the post-merger company. The proposed merger is currently pending the execution of a definitive agreement, shareholder vote and regulatory approval.

Net Element Inc. (NASDAQ: NETE) is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. The company’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element chairman and CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked on Deloitte’s Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in both 2017 and 2018, during which the company grew 190 percent and 183 percent, respectively. The company credits its progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

Net Element was also listed among South Florida Business Journal’s 2016 fastest growing technology companies.

Leveraging its suite of application performing interfaces (APIs) and connectors, Net Element powers commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Leading this innovation is chairman and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations like Aptito to e-commerce and retail payment transaction processing brands like Payonline and Unified Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed Tuesday's trading session at $10.23, off by 2.849%, on 371,945 volume with 2,744 trades. The average volume for the last 3 months is 1,688,982 and the stock's 52-week low/high is $1.472/$20.0783996.

Recent News

chart

Trxade Group Inc. (NASDAQ: MEDS)

The QualityStocks Daily Newsletter would like to spotlight Trxade Group Inc. (NASDAQ: MEDS).

Trxade Group (NASDAQ: MEDS), an integrated drug procurement, delivery and healthcare platform,has unveiled Bonum+, a business-to-business platform that bundles telehealth, a COVID-19 risk assessment tool and a Personal Protective Equipment (“PPE”) purchasing tool together. Available through MEDS subsidiary Bonum Health, the platform, which is the first of its kind, will be available through a secure mobile dashboard and is designed to ease pressure on employees who are mandated to report relevant health issues daily. To view the full press release, visit http://nnw.fm/UkpRr.

Trxade Group Inc. (NASDAQ: MEDS) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform (www.trxade.com) for transactions between independent pharmacists and drug distributors (B2B); a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

Trxade will leverage and scale its fully integrated model to execute the following growth strategies:

  • Increase share of pharmacist drug purchasing
  • Additional SKUs and expand product breath
  • Partner with Specialty and International Mfg.
  • Expand mail order licenses to all 50 states
  • Scale Delivmeds for consumer delivery nationwide
  • Integration with telemedicine
  • M&A Opportunities within drug value chain

Founded in 2010 and headquartered in Tampa, Florida, Trxade’s overarching corporate strategy is to penetrate the existing retail independent pharmacy marketplace and diversify the company’s pharmaceutical mix with additional specialty and acute care products. Trxade is advancing on this mission by focusing on three key niches in the health care market.

Business-to-Business (B2B)

The $330 billion U.S. pharmaceutical industry is comprised of more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. Roughly 24,000 of these facilities are independent pharmacies, which collectively spend approximately $93 billion a year on branded and generic drugs.

Trxade targets these independent pharmacies, leveraging a robust, “E-Bay/Kayak-like” technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

Trxade currently serves and transacts with more than one-third (10,250) of these independent pharmacies and facilitates over $10 million of drug purchases a month!

Consumer

Trxade also targets the “consumer side” of the pharmaceutical industry, aiming to lower prescription drug costs by attacking the inefficient value chain; offering drug price transparency and efficient buying; and, delivering drugs DIRECT to independent pharmacists and consumers.

The company operates a full-service mail order pharmacy for U.S. consumers, as well as a mobile app called “Delivmeds” (http://www.delivmeds.com) which enables SAME DAY home delivery of dispensed prescriptions.

Retail

Trxade’s Managed Services Organization (“TrxadeMSO”) enables its member independent retail pharmacies to get patients, process orders, and deliver or ship prescriptions to patients. TrxadeMSO provides access to encompassing network of pharmacies through the E-Hub software, allowing for timely and comprehensive medication fulfillment.

These offerings ensure the best-suited pharmacy receives the patient’s information, thereby ensuring appropriate medication coverage based on the patient’s location, payor coverage, and medication access/inventory. This will save the clinicians and their staff time as they benefit from efficiency and enhanced workflow management in script processing and fulfillment.

Health Care Market

The U.S. health care market currently hovers near $4 trillion and is expected to grow as the general population ages. This growth will have greater impact on consumers as out-of-pocket expenses also rise. Additionally, drug costs are paced to increase faster than the overall health care and well above inflation.

Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

Trxade’s fair online market platform targets the nation’s retail community and independent pharmacies, of which there are approximately 24,000 nationwide. TRxADE has found that independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The TRxADE S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving money by taking advantage of best purchase pricing.

TRxADE’s programs include:

  • TRxADE Exchange, which opens and widens the distribution channel to the retail, community pharmacy. A purchasing pharmacy can view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. This approach significantly enhances the competitive spirit of the exchange where the lowest price exists for each product at any given point in time. TRxADE has become a competitive tool for all progressive entities and is recognized for its easy searching of hard-to-find generic pharmaceuticals at substantially reduced prices.  
  • RX Guru™ is an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks (“PAC”) to ascertain trends and pricing variances that result in significant purchasing opportunities. RX Guru affords members the opportunity to continuously benefit from real price purchasing opportunities that are concealed from the rest of the industry. 
  • Product Shortage Database – TRxADE maintains the most comprehensive retail, specialty and acute care pharmaceutical product shortage database in the country. Other industry competitors mainly restrict their efforts to specialty and acute care product shortages and narrowly research oral generic products. TRxADE’s advanced prediction tools help members source those hard-to-find products at affordable costs in a timely and easy-to-search process. 

Management Team 

Trxade’s management team is rich in expertise within the pharmaceutical supply chain and is supported by a base of advisors and contractors who are experts in related fields of the pharmaceutical sector.

Suren Ajjarapu – Chairman of the Board, Chief Executive Officer and Secretary
Suren Ajjarapu has served as Trxade’s chairman of the board, CEO and secretary since 2014, and as the chairman of the board, chief executive officer and secretary of Trxade Nevada since its inception. Ajjarapu also serves as a chairman of the board for Feeder Creek Group Inc., since March 2018. Ajjarapu formerly was a founder, CEO and chairman of Sansur Renewable Energy Inc., a company involved in developing wind power sites in the Midwest, United States; a founder, president and director of Aemetis Inc., a biofuels company (AMTX.OB); a founder, chairman and CEO of International Biofuels, a subsidiary of Aemetis Inc.; and a co-founder, COO, and director at Global Information Technology Inc., an IT outsourcing and systems design company. Ajjarapu holds an M.S. in environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in international finance and management. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel – Director, President and Chief Operating Officer
Prashant Patel has served as Trxade’s full-time president and COO, and as a director since the company’s acquisition of Trxade Nevada in 2014, and as the COO and president and as a director of Trxade Nevada since its inception. He has been a president and member of the board of Trxade since August 2010. Patel is a registered pharmacist and pharmaceutical consultant with over 10 years of experience in retail pharmacy and pharmaceutical logistics. He is the founder of several pharmacies in the Tampa Bay area, in Florida. Since 2008, Patel has been managing member of the APAA LLC pharmacy. Since 2007, Patel has been a vice president of Holiday Pharmacy Inc. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

Trxade Group Inc. (MEDS), closed Tuesday's trading session at $6.25, off by 9.2888%, on 113,574 volume with 559 trades. The average volume for the last 3 months is 50,398 and the stock's 52-week low/high is $4.01000022/$11.6000003.

Recent News

chart

The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER)

The QualityStocks Daily Newsletter would like to spotlight The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER).

The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER)a producer of premium bottled alkaline water, flavor-infused waters and CBD-infused products, has scheduled a teleconference to review its financial report for the first quarter. The teleconference will be hosted by WTER president and CEO Richard Wright and CFO David Guarino. To view the full press release, visit http://cnw.fm/A5eo0. Also today, the company was featured in the 420 with CNW by CannabisNewsWire. Back in 2016, voters in Massachusetts elected to legalize cannabis in the state. Nearly four years later, the legal landscape of Massachusetts’ legal cannabis industry is still changing and shifting. Like in most states with a legal cannabis program, the industry is fairly young, and regulators are working together with stakeholders and consumers to create a regulatory framework that works for everyone.

Founded in 2012, The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88®, is a leading premier alkaline water brand available in bulk and single-serve sizes, along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88® delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts the company’s trademarked label ‘Clean Beverage’. Quickly being recognized as a growing lifestyle brand, Alkaline88® launched A88 Infusedâ„¢ in 2019 to meet consumer demand for flavor-infused products. A88 Infusedâ„¢ flavored water is available in six unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched the A88CBDâ„¢ brand, featuring a broad line of topical and ingestible products. These products are made with lab-tested full and broad-spectrum hemp and include salves, balms, lotions, essential oils, bath-salts, CBD infused drinks, tinctures, capsules, gummies and powder packs.

Innovation and Expansion

Founded in 2012, The Alkaline Water Company began with a mission to create the best-tasting water in the world. At the time, there were two emerging trends in health-conscious consumers: a growing interest in the alkaline diet and perceived health benefits of pink Himalayan rock salt. By combining these two concepts in an alkaline water and trademarking the name Alkaline88, The Alkaline Water Company began offering what it calls the smoothest tasting Clean Beverageâ„¢ in the U.S. enhanced-water category.

Now a top bulk alkaline-water brand (the company reported record sales in March and April 2020, surpassing March and April 2019 numbers by 114% and 171%, respectively), The Alkaline Water Company is committed to growing its national footprint through innovation and expansion. That mindset was evident as the company introduced eco-friendly aluminum bottles and branched out into flavor-infused waters; the company currently offers six different flavors: peach/mango, lemon/lime, raspberry, watermelon, blood orange and lemon.

The company’s commitment to innovation may be most evident in its newest product line: A88CBD. This line of CBD-infused products includes tinctures, capsules, gummies, salves, balms, hand and foot lotions, essential oils, bath bombs and bath salts, as well as CBD-infused drinks, water and beverage shots. These quality, CBD-infused offerings are all made with lab-tested, full-spectrum hemp and are conveniently packaged and perfect for on-the-go or at home use.

In addition, The Alkaline Water Company has implemented an aggressive growth strategy, with numerous organic initiatives focused on national multichannel, mass-market expansion through a direct-to-warehouse model and co-packing facilities that are strategically located within 600 miles of 95% of the U.S. population. In addition to this strong brick-and-mortar approach, the company recently launched a B2C e-commerce platform (www.A88CBD.com) and aggressive digital-marketing campaigns.

Clear Advantages in a Growing Market

With consistent growth year over year, the company reported $32.2 million in revenue in fiscal 2019 and has emerged as a growth leader in the functional (value-added) waters space, which is the fastest-growing segment of the bottled water industry.

The Alkaline Water Company’s efforts are focused on its clear competitive advantages, including its strong marketing (the inclusion of alkaline in product names); existing grocery channels, which feature excellent relationships and a nationwide broker network; distinctive branding; proprietary technology, which produces great-tasting, high-quality water, infused drinks and other products; and price, with a broad range of products in all formats, from bulk bottles to single serve.

As the company focuses on strategic growth, it is eyeing the impressive potential of a market that is on a strong upswing. Annual bottled water sales have now surpassed soda consumption, with soda sales in the United States having declined by $1.2 billion over the past five years. Some research indicates that the global bottled water market will reach an estimated $280 billion this year, while the CBD market is forecast to top $20 billion by 2024.

With its products available in all major trade channels, including grocery stores, drug stores, c-stores and big-box retailers, The Alkaline Water Company is also looking to expand into new spaces, such as health and beauty, hospitality and specialty retailer locations.

Seasoned Management Team

The Alkaline Water Company is led by an experienced team focused on the company’s core strategy of building a national retail footprint and extending its lifestyle brands into other consumer packaged goods categories.

Richard A. Wright, President, CEO and Co-Founder of The Alkaline Water Company Inc., oversees all aspects of the business, successfully guiding the company through strategic opportunities and delivering greater than 50% growth since the company’s inception. A passionate and versatile leader with a strong track record of innovation, collaboration and achieving goal-driven results, Wright is a serial entrepreneur with more than 41 years of experience. Early in his career, he spent years at one of the ‘Big Four’ accounting firms, working his way up to Regional Director of Tax and Financial Planning. As a CPA, entrepreneur and former CFO, Wright brings extensive knowledge of finance, operations, sales and marketing to the team, and he has participated in hundreds of M&A transactions throughout his career.

David Guarino, CFO, Secretary, Treasurer and Director, earned a Bachelor of Science in accounting and a Master of Accountancy from the University of Denver. From 2008 to 2013, Guarino was President and a Director of Kahala Corp., a worldwide franchisor of multiple quick-service restaurant brands with locations in 49 states and more than 25 countries. From 2014 to 2015, Guarino was President of HTI International Holdings Inc., a technology company focused on forward osmosis water filtration technology.

Frank Chessman, National Sales Manager, is a graduate of the University of Southern California’s Marshall School of Business. He spent 25 years with Ralph’s Grocery, Kroger’s largest division, working at many levels before ultimately becoming Vice President of Advertising & Marketing. He then served 14 years as Executive Vice President at Simon Marketing. Chessman has more than a decade of experience in the beverage manufacturing industry.

Brian Sudano, Director, is managing partner of Beverage Marketing Corporation and BMC Strategic Associates. Sudano’s experience covers nearly the entire beverage industry, from energy drinks to wine, with special expertise in beverage alcohol by virtue of varied industry experience across a broad range of projects. Sudano manages several major clients, providing ongoing strategic and market advice and leading projects in strategic planning, market entry analysis and planning, sales/distribution, business modeling, brand repositioning and international opportunity assessment. He has spoken at many beverage industry events and is a contributing editor at Beverage World magazine.

Aaron Keay, Chairman, has been a successful investor, entrepreneur and financier to multiple small cap and startup companies over the last decade. During his time with these companies, he served in advisor, board-member and senior-management roles. His experience ranges across multiple sectors in mining, biotech, health and wellness, tech and cannabis, where he has invested and raised more than $500 million.

The Alkaline Water Company Inc. (NASDAQ: WTER), closed Tuesday's trading session at $1.63, off by 4.6784%, on 1,619,433 volume with 4,539 trades. The average volume for the last 3 months is 1,535,095 and the stock's 52-week low/high is $0.400000005/$2.79999995.

Recent News

chart

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, announced the appointment of three new highly qualified individuals to its board of directors (http://ibn.fm/YAU80). The three new board members — Dr. Nancy Chung-Welch, PhD; Charles L. Nuzum, CPA; and Greg St. Clair — bring with them more than a century of invaluable experience in business development, marketing and financial expertise in the life-sciences space. Also today, the company was featured in a publication from BioMedWire, examining how POAI outlined the company’s recent accomplishments in a letter released to shareholders today. The letter, sent from CEO Dr. Carl Schwartz, also summarized voting recommendations from POAI’s Board of Directors regarding two proposals that are scheduled for shareholder vote next month. “Predictive Oncology is committed to executing our strategic vision to develop and commercialize an offering that will enable us to support the improvement in healthcare outcomes for oncology patients and increase value for our shareholders,” stated Schwartz in a press release containing the letter. “Over the last six months we have been diligently assembling a portfolio of assets and aligning our capital and governance structures to help us achieve this vision.” To view the full press release, visit http://ibn.fm/Epqmf. Additionally, BioMedWire highlighted the company in an article which looks at how the most complex and least-understood organ in the body is the brain and it is made up of many specialized areas that work together. Now modern methods, such as pharmacology and gene editing, can show how certain drugs and genes affect the cells in specific regions of the brain.

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Tuesday's trading session at $1.57, off by 7.6471%, on 1,904,045 volume with 3,232 trades. The average volume for the last 3 months is 1,045,598 and the stock's 52-week low/high is $1.25/$6.42799997.

Recent News

chart

LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF)

The QualityStocks Daily Newsletter would like to spotlight LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF).

LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) was highlighted today in a publication from BioMedWire, examining how, for thousands of people who have suffered terrible blast injuries, the only remedy to this is always amputation. Barrel bombs and other explosive devices usually cause the worst form of these injuries. These explosions are dangerous, damaging the limbs of those who survive them. Since most of these blasts still occur in developing nations without sophisticated medical care, the victims are continuously subjected to amputations.

LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) is a molecular diagnostics company that develops genetic analyzers for rapid detection of pathogens at the point-of-need.

Based in the greater-Boston, Massachusetts area, the company’s fully automated genetic analyzer for pathogen detection, the MiQLabâ„¢, is designed to deliver reference-quality data with ease of use. MiQLab’s technology screens samples for up to 27 different targets at once—looking for pathogens and antimicrobial resistance factors—and returns results in approximately one hour. It is designed to be operated at the site of sample collection to avoid the delay associated with shipping and manually processing samples. This technology is designed for use in multiple markets, including human and veterinary diagnostics, as well as food safety testing ($12.9B, $2.2B, and $23.4B markets, respectively).

Portfolio Benefits

Rapid, automated pathogen detection

LexaGene’s MiQLab pathogen detection system offers rapid and sensitive testing to markets in need of better vigilance against pathogens that could endanger health and harm public safety and the bottom line. The company’s disruptive technology is on-demand and offers results in approximately an hour.

End users collect a sample, load it onto the MiQLab genetic analyzer with a sample preparation cartridge, enter a sample ID and press ‘go’.

MiQLab is open-access, which allows users to easily customize their own tests, in addition to running the company’s own validated tests. No comparable technology exists on the market today for automating customized testing. The open-access market is over $20 billion in value and includes industries like pharma and biotech that currently need an automated method of performing PCR testing in a cost-efficient way.

Improved COVID-19 Testing

As the COVID-19 pandemic continues to pose a threat to global safety, the need for improved testing procedures has been well established. LexaGene’s technology is automated and designed to be used at the point-of-need, thereby avoiding the 12- to 24-hour shipping time. Plus, it performs sample preparation and the gold standard RT-PCR chemistry for exceptional data quality in about one hour.

Because LexaGene’s open-access instrument can be rapidly configured to detect novel pathogens, it is ideally suited to prevent pandemic spread with its easily deployed testing that facilitates rapid quarantine-related decision making.

This speed is in stark contrast to competitor point-of-care technologies that have reagents pre-embedded into complex and expensive cartridges that are only manufactured at specialized production sites – making it impossible to rapidly meet a swift increase in demand.

According to Dr. Jack Regan, LexaGene’s CEO and founder, the world needs easy-to-use, fully automated pathogen detection instruments operating at points-of-need that can be equipped with tests to detect a novel pathogen within a week of knowing its genetic sequence. For this pandemic, the lack of such technology forced the majority of testing to occur in distant reference laboratories, making rapid decisions on quarantine impossible and making the likelihood of successful containment remote.

Regan explained in a press release (http://nnw.fm/Vz5Ju), “LexaGene expects to be the first company to commercialize an automated open-access microfluidic technology designed for use at the point-of-need that can be configured to detect a novel pathogen in just a week’s time of its emergence – for use on-site to return results in one hour – and improve our chances of successful containment.”

Market Potential

LexaGene’s technology has a wide range of applications across many other markets, including biotech and pharma testing, water quality monitoring, agricultural testing, biodefense, and use at point-of-need at border crossings, military bases, aircraft carriers and cruise ships.

Markets for customized testing solutions are poised for significant growth. Industry analysts forecast considerable expansion of many of LexaGene’s potential target markets in the coming years, including:

  • The genotyping sector, forecast to reach a valuation of $31.9 billion by 2023;
  • PCR assays, expected to make up a $7 billion market opportunity by 2026;
  • The sample prep market, forecast to eclipse $9.3 billion by 2025;
  • Water quality monitoring, set to grow to $1.59 billion by 2022; and
  • Agricultural testing, anticipated to reach $6.29 billion by 2022.

LexaGene’s patented microfluidic system was invented by company CEO Regan, a leading scientist who developed a bio-warfare surveillance instrument that has been adopted by the Department of Homeland Security. Regan is also known for developing an instrument that detects respiratory pathogens from nasal swab samples. The development of these instruments was supported by $20 million in government funding.

Management Team

LexaGene’s experienced leadership team drives company growth with a focus on innovation, pursuing unique market opportunities and providing shareholder value.

Dr. Jack Regan, Chief Executive Officer & Director, is the inventor of the company’s flagship automated pathogen detection technology, the MiQLab. Before founding LexaGene, he led a team of scientists at Bio-Rad Laboratories (NYSE: BIO) in developing tests for detecting pathogens, cancer and neurological disorders using droplet digital PCR. Prior to Bio-Rad, Regan helped QuantaLife, a startup company, bring its product from concept to commercialization, where it was subsequently acquired by Bio-Rad. He has also worked at Applied Biosystems/Life Technologies on automated sample preparation and did his post-doctoral training at Lawrence Livermore National Laboratory. His doctoral training at the University of California San Francisco focused on influenza viral replication.

Daryl Rebeck, President, has over 20 years of capital market experience with an established international financial network. Rebeck was a vice president and senior investment advisor with Canada’s largest independent investment bank, Canaccord Genuity, where he was responsible for raising significant risk capital for growth companies, with a particular focus on natural resources and medical technology. He has since worked to provide management expertise and grow shareholder value. He served as senior VP of corporate finance of Auryn Resources (NYSE: AUG), a $250 million market cap mining exploration company.

Jeffrey Mitchell, CFO, boasts over two decades of financial and SEC experience. Before joining LexaGene, he served as controller and director of finance, overseeing areas such as public company financial reporting, audits, and financial planning and analysis for Palomar Medical Technologies Inc. In addition to his many years at Palomar, Mitchell has served in numerous financial and strategic advisory roles for medical device, imaging and diagnostic companies.

LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF), closed Tuesday's trading session at $0.65886, off by 4.513%, on 665,369 volume with 273 trades. The average volume for the last 3 months is 327,258 and the stock's 52-week low/high is $0.303799986/$0.928245007.

Recent News

chart

Cannabis Global Inc. (CBGL)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Global, Inc. (CBGL).

Cannabis Global Inc. (OTC: CBGL) was featured today in the 420 with CNW by CannabisNewsWire. 2020 looked to be the year for cannabis. Several states had plans to legalize cannabis via either voting on the November ballot or inclusion in the budget at the start of the year, but the coronavirus threw everything into disarray. The resultant health and economic crisis forced many of them to postpone legalizing cannabis to 2021 and beyond. However, some states were able to take the steps needed to initiate legalization despite the crisis. Vermont, for instance, seems poised to advance legal marijuana sales very soon.

Cannabis Global Inc. (CBGL) is an innovator in the field of cannabinoid nanoparticles and infusion technologies with several important cannabinoid patents filed and an active research and development program underway. The company was reorganized during June 2019 and announced its intent to enter the cannabis sector. In August 2020, it changed its corporate identity from MCTC Holdings Inc. to Cannabis Global Inc. The company is headquartered in Los Angeles, California.

With the hemp and cannabis industries rapidly expanding in terms of market size, acceptance and number of market participants, CBGL plans to concentrate its efforts on the middle portions of the hemp and cannabis value chain. The company is actively pursuing R&D programs and productization of advanced cannabinoid delivery systems, based on solid polymeric nanoparticles and fibers. These technologies hold the promise to revolutionize the science of cannabinoid bio-enhancement for use in foods, beverages, consumer products and in transdermal applications. Because of nanoparticles’ ability to be quickly absorbed into the bloodstream, nanotechnology has been utilized in the food and drug industry for some time and has the potential for tremendous growth in the cannabis industry (http://nnw.fm/v6RQ6).

Cutting-Edge Technology

CBGL is at the cutting-edge of the cannabis industry’s trends with its emphasis on polymeric nanotechnology. This is not to be confused with the more basic oil-in-water nano-emulsions currently marketed to the food and beverage industry. The company’s polymer-based particles offer significant loading of active ingredients and unmatched flexibility and customization, allowing for myriad combinations of cannabinoids with unique performance characteristics. CBGL believes polymeric nanotechnology particles will be a critical technology area for the cannabinoid formulation marketplace.

The company continues to build its R&D program, specifically researching the development of improving methods to make cannabinoids available to living systems. Instrumental in the research program is the development of novel polymeric nanoparticles and nanofibers. These have the potential to elevate the potential of cannabinoid products in the following ways (http://nnw.fm/cK3Bl):

  • Significantly improving bioavailability
  • Allowing for ultra-high loading rates
  • Enhancing customization of cannabinoid combinations
  • Improved dosing precision
  • Providing more control in release parameters

CBGL leadership understands the importance of developing intellectual property (IP) in the ever-evolving cannabis industry. A recent Forbes article described IP as “critical for creating true differentiation between companies and their product and service offerings” (http://nnw.fm/57Fjh). Recognizing the importance of IP, CBGL has been consistent in its application for patents to protect its innovative nanotechnology applications.

Patents

CBGL has now filed four patents on its cannabinoid delivery technology systems:

  • The company first collaborated with Cannabis Nanosciences Inc. on technologies. This became the basis for its first patent filing on an innovative edible dissolvable film for cannabinoid ingestion.
  • Its second patent filing for cannabinoid nanoparticles combined TPGS, a water-soluble form of vitamin E.
  • Its third patent filing involved a unique 4th dimension, 3D printed cannabinoid delivery system for beverages.
  • Its fourth patent, considered its most significant, broadly covers many aspects of nanoparticles and nano fibers comprising one or more cannabinoids disposed at least partially within a water-soluble medium.

Collaborations

CBGL collaborated with Marijuana Company Inc. (OTCQB: MCOA) subsidiary hempSmart Inc., under a hemp extract and CBD product supply agreement wherein hempSmart will utilize its extensive network of marketing partners to market CBGL’s powered drink mixes and other CBD edibles online. These products are designed for the dry beverage and edibles sector and will be supplied by CBGL. They incorporate the company’s patent-pending cannabinoid infusion technologies and will be trademarked as Hemp You Can Feel (TM) and Gummies You Can Feel (TM).

Leadership

CBGL CEO and chairman Arman Tabatabaei boasts 15 years of management and operations experience and is considered an expert at data collection and analysis relative to resource management, risk forecasting, and profit and loss management. He has acted as a consultant with Cannabis Strategic Ventures (OTCQB: NUGS) and played an instrumental role in improving operations at Sugarmade Inc. (OTCQB: SGMD) relative to the company’s hydroponic growth supplies initiatives.

CBGL founder and director Robert Hymers also brings a seasoned perspective, having had significant experiences in the cannabis industry and as a financial executive and consultant. He is the managing partner of Pinnacle Tax Services in Los Angeles and was previously CFO and director of Marijuana Company of America Inc. (OTC: MCOA). He is currently a member of the Strategic Advisory Board at Massroots Inc. and acts as a consultant to both Cannabis Strategic Ventures Inc. and Sugarmade Inc. Hymers’ background in tax accounting, auditing, SEC reporting, mergers and acquisitions, and corporate finance has immense value in his current position at Cannabis Global.

Cannabis Global, Inc. (CBGL), closed Tuesday's trading session at $0.15499, up 3.3267%, on 17,366 volume with 14 trades. The stock's 52-week low/high is $0.05/$3.00.

Recent News

chart

Sustainable Green Team Ltd. (SGTM)

The QualityStocks Daily Newsletter would like to spotlight Sustainable Green Team Ltd. (SGTM).

Sustainable Green Team Ltd. (OTC: SGTM), through its subsidiaries, including National Storm Recovery LLC (DBA Central Florida Arbor Care and Mulch Manufacturing Inc.), provides tree services, debris hauling, removal and bio-mass recycling, manufacturing, packaging and sales of next-generation mulch products. The company’s primary corporate objective is to provide a solution for the treatment and handling of tree debris that is historically sent to local landfills and disposal sites, creating an environmental burden and pressure on disposal sites around the nation.

Environmentally Friendly

SGTM and the solutions provided by its Sustainable Green Team are founded in sustainability. The company’s vertically integrated operations begin with the collection of tree debris through its tree services division and collection sites. Tree bio-mass is then moved through the processing division for recycling and manufacturing into a variety of organic, attractive, next-generation mulch products to be packaged and sold to retailers, landscapers, installers and garden centers.

The company’s solutions create a synergistic and environmentally beneficial solution to tree and storm waste disposal that historically has created an environmental burden on landfills and disposal sites around the nation.

SGTM’s customers include governmental, residential and commercial customers and now big box retailers. The company is headquartered in Florida.

Strategic Acquisition

SGTM in February 2020 acquired 35-year-old industry leader and innovator Mulch Manufacturing Inc., an Ohio corporation. Structured as a share exchange, this strategic partnership provides SGTM with a significantly larger footprint in the mulch industry.

The acquisition includes Mulch Manufacturing’s national and international distribution agreements, an increase in production and packaging capacity, and its sales contracts with numerous big box retailers. Mulch Manufacturing includes mulch production, sawmill operation, Natures Reflections colorant manufacturing and equipment manufacturing.

Next-Gen Products

SGTM’s vision and commitment to the environment is paired with Mulch Manufacturing’s revolutionary “next-generation” mulch product, Nature’s Reflection’s Softscape®.

Softscape mulch products, created from natural forest products, are color-enhanced with environmentally safe colorants to provide four-year color retention and are free from contaminants. Safe for people and pets, Softscape allows water and air to penetrate soil and roots, which is vital to plant health and growth.

Expansion Plans

SGTM plans to expand its operations through a combination of organic growth, through its partnership with a nationally recognized waste disposal company, and through strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified.

The company has received final zoning approval for its 100-acre site, located in Lake County, Astatula, Florida, which will serve as its flagship tree debris collection site. The facility will also house the company’s mulch manufacturing, soil composting and production bagging. This prime location includes a 5,000-square-foot building that contains warehouse and office space. The 100-acre property can accommodate millions of cubic yards of organic debris and will allow SGTM’s debris hauling division to realize significant savings on its transportation costs.

SGTM has chosen as its new headquarters the 100,000-square-foot Mulch Manufacturing building in Jacksonville, Florida. The facility comprises centralized operations of Mulch Manufacturing Inc. and National Storm Recovery LLC and has ample room to expand as needed.

Leadership

SGTM’s leadership team boasts more than 40 years of next-level experience with mulch manufacturing, treating and caring for trees. This team is guided by a roster of highly qualified professionals:

  • Tony Raynor, Chief Executive Officer
  • Edward Lee, Chief Operating Officer
  • Ralph Spencer, Director of Business Development, Strategic Acquisitions
  • Steve Ogden, ISA-Certified Arborist
  • Rick Starcher, Master Chemist
  • Peder K. Davisson, Esq., Corporate/Securities Counsel

Sustainable Green Team Ltd. (OTC: SGTM), closed Tuesday's trading session at $1.75, up 29.6296%, on 2,872 volume with 15 trades. The stock's 52-week low/high is $0.05/$2.19000005.

Recent News

chart

Pac Roots Cannabis Corp. (CSE: PACR)

The QualityStocks Daily Newsletter would like to spotlight Pac Roots Cannabis Corp. (PACR).

Pac Roots Cannabis Corp. (CSE: PACR) is a Canadian cannabis company dedicated to producing premium-quality strains and products by leveraging a genetics-focused approach.

The company began operations in 2012, with activities primarily directed toward exploration and development of mineral properties in Canada. Today, it is focused on cannabis and hemp cultivation, leveraging high-end genetics and specialized cultivars to produce top quality products. Pac Roots has announced multiple promising initiatives in recent months, including its formation of an outdoor premium hemp joint venture with partner Rock Creek Farms in British Columbia, Canada, and its agreement to acquire all issued and outstanding shares of a firm holding 250 acres of land in the famed Fraser Valley Region of British Columbia.

Pac Roots is also in the process of completing its 20,000 square foot cultivation facility in Lake Country, British Columbia. The facility is expected to feature approximately 7,600 square feet of cultivation space that will enable the company to cycle through an elite line of 350+ unique, high-grade cultivars. Pac Roots expects to receive a cultivation license for the facility in the fourth quarter of 2020.

High-End Selectively Bred Genetics

Pac Roots focuses on high-end genetics in order to maximize the quality of its products while maintaining high yields and profit margins.

Through the process of artificial selection, farmers and cultivators have been adapting their plants to develop particular phenotypic traits for generations. Historically, this practice was restricted to underground cannabis producers developing their own strains.

The legalization of the cannabis industry has given producers access to thousands of cultivars located throughout the world while accelerating research into cannabis genetics. By carefully selecting strains, growers can control the size, color, smell, density and texture of cannabis buds, thereby creating distinctive, premium cannabis products.

Plants are bred to thrive in specific growing environments. This maximizes the yield of high-quality, resilient cannabis. Medical cannabis strains can also be tailored for specific medicinal purposes.

A strategic partnership with Phenome One, a plant breeding management and analytics firm, gives Pac Roots access to some of the world’s best cannabis genetics from the largest genetic library in Canada. The company is using these genetics to develop unique strains featuring a variety of beneficial characteristics.

The company’s 350+ licensed live cultivars and over 1,800 seed varieties are the result of a meticulous gene selection process, through which as many as 600 individual plants may be grown to produce a single strain. Selecting optimized genetics in this way provides benefits beyond simply producing a high-end product. In addition to potency and bud quality, cannabis plants are bred for yield and resilience. By selecting genetics that result in larger and more numerous buds on each plant, Pac Roots is able to grow more cannabis per grow light.

Breeding plants to be more resilient also reduces the cost and labor required. These factors, combined with the premium price point associated with top-quality cannabis, have the potential to improve Pac Roots’ overall profit margin.

Partnership with Phenome One

Pac Roots has secured its cultivars through a strategic licensing agreement with Phenome One. Under the agreement, Pac Roots has unlimited access to Phenome One’s live genetic library, including any of Phenome One’s cultivars and its growing, breeding and cloning IP.

Phenome One is an agricultural technology company focused on providing software solutions to seed companies. Phenome One’s platform gives its partners access to a massive database of detailed information on over 350 unique cannabis cultivars to support each stage of the breeding process. Each cultivar has been laboratory analyzed and rigorously field-tested, with data going back more than 30 years.

Using Phenome One’s data, Pac Roots plans to grow a variety of cannabis plants optimized for certain traits. One such trait will be plants with an abundance of cannaflavin, a rare terpene with high anti-inflammatory properties. Phenome One’s library could enable Pac Roots to produce plants that are bred to thrive in a range of different growing climates, including plants suited to grow in cold weather and plants that are resilient to region-specific fungi.

Joint Venture with Rock Creek Farms of British Columbia

Pac Roots recently entered a definitive investment agreement with Rock Creek Farms, a reputable agricultural enterprise, for a 100-acre commercial hemp operation in Rock Creek, British Columbia. The growing space is located in the highly lucrative farming area known as the ‘Golden Mile’ in the South Okanagan Valley of British Columbia. (http://nnw.fm/Gbf9I).

Under the agreement, the two companies have formed an outdoor premium hemp joint venture company to which Pac Roots is providing an aggregate of $450,000 in capital and Rock Creek Farms is contributing two commercial leases for 100+ acres of growing space, along with cultivation licenses, agricultural infrastructure and equipment, consulting services, intellectual property relating to hemp operations and proprietary biomass storage methods. Pac Roots holds a 60 percent interest in the project.

About 127,500 premium hemp CBD seedlings were planted across 100 acres as of early July 2020. The joint venture is planting a premium grade CBD hemp variety utilizing the rich native soil and both traditional and custom farming techniques.

“Our operational partners at Rock Creek Farms bring decades of generational farming expertise in one of Canada’s pre-eminent growing regions,” Pac Roots President and CEO Patrick Elliott said in a news release detailing the venture. “It will be an exciting outdoor growing season for the joint venture as we anticipate a successful harvest in the fall.”

Infinite Development Possibilities at Fraser Valley Property in British Columbia

In mid-July 2020, the company initiated a share purchase agreement with 1088070 BC. LTD. (“1088”) and its shareholders for the acquisition of all issued and outstanding shares of 1088 (http://nnw.fm/xlpw7). Notably, 1088 owns and controls 250 acres of land spread over nine parcels in the Fraser Valley Regional District.

The Fraser Valley Regional District is one of the most productive and intensively farmed areas of Canada, offering access to high-quality soil, favorable climate, water and a local market of 2.5 million people. Agriculture in this region yields an annual economic value of more than $3 billion.

The closing date for the transaction is slated for September 4, 2020, after a 51-day due diligence period. According to Elliott, the addition of such a significant package of land is a major step for Pac Roots.

“This land has no zoning restrictions and is not situated within the agricultural land reserve, which provides for infinite development possibilities,” Elliott added in a July 2020 news release.

Board of Directors member Chad Clelland also welcomed the acquisition, adding that between Fraser Valley and Rock Creek – both of them among the most productive agricultural regions in Canada – Pac Roots is very well positioned for production and the future development of its hemp and cannabis infrastructure.

The RAD Americas Genetic Program – Research and Development in Americas Genetic Program

Pac Roots intends to deploy a global R&D program focused on rigorously testing elite strains in various rich agricultural regions throughout the Americas, with a goal of mass selection to achieve the utmost environmental resilience while achieving notable quality and yields. From seed to software, collection data, proprietary techniques and custom nutrient formulas, Pac Roots and Phenome will provide the specific knowledge to cultivators in different climates in order to achieve optimal yields for THC, CBD, CBG and other unique cannabinoids. R&D from global testing programs situated throughout the Americas will allow the partnership to deploy and stress test a range of suitable cultivars in the world’s lowest cost outdoor growing regions.

The company expects an industry shift in 2020 from the COVID-19 global pandemic. The ‘new normal’ will bring more focus on efficiencies and optimal yields to deliver a cost effective, high quality product to the end user. There has been much to be learnt from the inefficiencies in the cannabis industry in recent years, which have been detrimental to the credibility of the sector. Pac Roots is well positioned to enter the scene and take advantage of the deficiencies, reinforcing the notion that genetics and flawless growing techniques are paramount to success. Genetics and systems innovation may be the most overlooked components when comparing cannabis to other established agricultural crops. Pac Roots plans to invest into cannabis R&D to ensure a solid foundation is built that will be used by cannabis farmers worldwide.

Through its RAD Americas Development and Innovation, Pac Roots is focused on:

  • Deploying one of the largest live genetic libraries in Canada, diversified for high yield output and unique climates
  • Continued stress testing for indoor, high yield, THC and medicinal genetics
  • Continued stress testing for outdoor, high yield, THC and medicinal genetics
  • Exotic, genetic cloning for the luxury, high margin, cannabis flower market
  • Psychoactive/medicinal ratio testing for effect and
  • Unique Cannabinoid and terpene elevation and isolation.

Through its RAD Americas Field Testing System, the company is focused on:

  • Global testing in different microclimates to assess genetic and complete systems for optimal yields
  • Data collection, testing and optimization to prove process for commercial implementation and
  • High quality yield testing for THC, CBD, CBG and other unique medicinal cannabinoids.

Lake Country Cultivation Facility near Kelowna, British Columbia

Pac Roots is in the process of completing its 20,000 square foot cultivation facility in Lake Country, British Columbia. The facility is expected to feature approximately 7,600 square feet of cultivation space that will enable the company to cycle through its line of high-grade cultivars. Pac Roots plans to submit a video evidence package of the facility build under Health Canada’s Cannabis Tracking and Licensing System, and the company expects to acquire its cultivation license in the fourth quarter of 2020.

Lake Country is a municipality located just outside of Kelowna in the Okanagan region of British Columbia. For decades, the region’s favorable growing climate has made it a hub for cannabis cultivation. As the Canadian legal cannabis industry ramps up, the Okanagan region is attracting attention from dozens of cannabis companies, including some of the industry’s biggest names. The region’s strong agricultural history has left it rich with experienced agricultural workers and an abundance of Agricultural Land Reserve (ALR) property.

Management Team

Patrick Elliott, MSC, MBA, President and CEO of Pac Roots Cannabis, is also the President & CEO of Lexore Capital Corp., a private resource and cannabis investment company, as well as Phenome One Corp., a full-service cannabis farming company focused on elite strain selective breeding. Elliott brings over 15 years of corporate finance, mineral exploration and financial markets experience to the Pac Roots team. He is a graduate of the University of Western Ontario in geology and holds an MSc. in mineral economics and an MBA from Curtin University of Technology in Perth, Australia. Elliott specializes in economic resource evaluation, financial modeling, CAPEX estimation, corporate development and finance. Combined with his technical knowledge, Elliott has a wealth of contacts in the financial sector.

Marc Geen, Founder and Strategic Operations Advisor, is a fourth-generation British Columbia farmer who has been active in the legal medical marijuana industry for more than 10 years – consulting on, complying with, and participating in the MMAR, MMPR and ACMPR programs. Prior to co-founding Speakeasy Cannabis Club Ltd., Geen spent 14 years as Head of Operations for Kettle Mountain Ginseng Ltd., one of North America’s largest ginseng producers. With the experience gleaned from a long career in large scale commercial farming, Geen has been able to apply many cost-effective farming practices to the outdoor, indoor and greenhouse cultivation of cannabis. Geen is also the co-creator of a full line of cannabis extract products designed under ACMPR regulations.

Matt McGill, Director, has a strong background in both commercial and residential real estate and has played a major role in many development projects. McGill, through McGill Realty, has established a tremendous commercial and residential outfit servicing British Columbia’s Fraser Valley and the lower mainland. McGill is skilled at crafting strategic financing options for corporations and has a substantial network of retail and institutional clients.

Chad Clelland, Director, has experience in the sector dating back to 2009, when he purchased Medicalmarijuana.ca, which became an information portal for thousands of patients, doctors and growers. Through this company, he and his team have helped thousands of Canadians find legal, safe medication. His team also consulted, designed and submitted dozens of applications to the government under the MMPR, ACMPR and Cannabis Act. In 2011, Clelland co-founded Greenleaf Medical Clinic, which is now recognized as a training facility by the University of British Columbia and offers preceptorships to physicians, nurse practitioners and pharmacists. He also co-founded Folium Life Science in 2013, an approved Canadian Licensed Producer. His roles in these organizations have included Chief Operating Officer, head of security, alternate master grower and alternate responsible person in charge.

Josh Bromley, Senior Cultivation Strategist, is a second-generation farmer with over two decades of experience farming, breeding, cultivating and selecting unique cultivars for the medical community. He is an expert in plant science and possesses a comprehensive knowledge of cultivars and a mastery of medicinal implementation. Bromley has developed proprietary farming systems, as well as low cost/high output nutrient systems. Through thoughtful design and engineering, he has been able to consistently show improvements in crop yields, pathogen resiliency and quality.

Pac Roots Cannabis Corp. (PACR), closed Tuesday's trading session at $0.38, 8.57%, with 1 trade. The average volume for the last 3 months is 57,989 and the stock's 52-week low/high is $4.54500007/$9.22999954.

Recent News

chart

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF)

The QualityStocks Daily Newsletter would like to spotlight Canopy Rivers Inc. (RIV) (CNPOF).

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) is the venture capital investment platform of Canopy Growth Corporation (TSX:WEED, NYSE:CGC).

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers collaborates with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. Headquartered in Toronto, Canada, Canopy Rivers has developed an ecosystem of complementary cannabis operating companies operating throughout the cannabis value chain.

Canopy Rivers, in collaboration with Canopy Growth, has established a diverse portfolio of cannabis industry investments that includes domestic and international companies, licensed producers, late-stage licensed producer applicants, pharmaceutical formulators, brand developers and distributors, retail networks, and technology and media platforms. Investments are customized for each counterparty and include a balanced mix of equity, debt, royalty and profit-sharing agreements.

Canopy Rivers’ expanding portfolio includes:

  • Agripharm Corp. (private) is an ACMPR licensed producer, acquired by Canopy Growth in January 2017. In November 2017 Agripharm completed a joint venture with globally recognized partners Green House Seeds and Organa Brands. Canopy Growth has sublicensed proprietary technology, trademarks, genetics, know-how and other intellectual property from Agripharm to distribute the suite of Green House and Organa Brands products across the country, when permissible.
  • CanapaR Corp. (private) owns 80% of CanapaR Italy, a Sicily-based company focused on developing and commercializing Italy’s local hemp cultivation industry through its partnership with the renowned Department of Agriculture at the University of Catania and its rapidly building extraction capabilities for the production of organic CBD oil. CanapaR Italy’s outsource farming model with local Sicilian farmers and its university partnership will provide it with a low-cost source of organic CBD oil, which is increasingly used as an input into new commercial products in the growing health and wellness industries.
  • Civilized Worldwide Inc. (private), is a media and lifestyle brand with offices in New Brunswick and California that embraces and highlights modern cannabis culture. Civilized aims to engage the millions of productive, motivated people who choose to enjoy cannabis responsibly as part of their lifestyle. Reaching 2+ million unique visitors per month, North America-wide, Civilized produces engaging content for and about people who enjoy cannabis responsibly.
  • James E. Wagner Cultivation Ltd. (TSXV:JWCA) was founded in 2007 by third generation agricultural and cannabis cultivators. JWC is the first entirely aeroponic producer of cannabis in Canada, and its patent-pending aeroponic production technology, called GrowthStormTM, allows for perpetual harvesting and improved yields. The company was issued a license to cultivate from Health Canada in January 2017 and a subsequent sales license in March 2018.
  • LiveWell Foods Canada Inc. (TSXV:LVWL) was established in 1993 as a nutritional lifestyle company, and operates in the production of fresh produce and food technology. The company’s O-Hemp division distributes bulk and retail hemp products through its existing channel partners. LiveWell entered into a strategic agreement with Canopy Rivers and Canopy Growth in April 2018.
  • PharmHouse (private) is a joint venture between Canopy Rivers and the principals and operators of leading North American greenhouse produce companies. PharmHouse has arranged to acquire a newly built 1.3-million-square-foot greenhouse located in Leamington, Ontario.
  • Radicle Cannabis Inc. (private) is an ACMPR-licensed cannabis company based in Hamilton, Ontario backed by a management team that brings extensive experience in regulated industries, retail distribution, tobacco and pharmaceutical development, as well as Award-winning cannabis horticulturist breeders and medical professionals.
  • Solo Growth (TSXV:ALZ) is a new cannabis retail concept that will operate locations under the name “YSS by Solo,” relying on the expertise of a management team comprised of founding shareholders, senior officers and board members of Solo Liquor Stores Ltd., a leading Canadian liquor retailer. Solo Growth was established through a recapitalization of Aldershot Resources Ltd.’s corporate structure that will allow the company to execute a new retail-focused cannabis business strategy.
  • Spot Therapeutics Inc. (private) is an applicant that was acquired by Canopy Growth in August 2017 to solidify its Maritimes expansion strategy and less than four weeks later Canopy Growth signed a supply MOU with the New Brunswick government. Canopy Rivers purchased the property and entered into a long-term lease and committed funding agreement with Canopy Growth.
  • TerrAscend Corp. (CSE:TER) cultivates high-quality cannabis in an indoor hydroponic facility, backed by a strategic investor boasting a strong background in the pharmaceutical space and an extensive portfolio of specialty pharma assets.
  • Vert Mirabel (private) is a joint venture that was established in December 2017 between Canopy Rivers, Canopy Growth, and Les Serres Stephane Bertrand. Bertrand is a large-scale greenhouse operator located in Mirabel, Quebec, and the largest grower of pink tomatoes in the country. With guidance and assistance from Canopy Growth, the greenhouse has been upgraded and retrofitted for cannabis production and was licensed by Health Canada in May 2018.

As the company’s portfolio continues to develop, each constituent benefits from opportunities to collaborate with Canopy Growth and among themselves. Canopy Rivers believes this formula results in an ideal environment for innovation, synergy and value creation for Canopy Rivers, Canopy Growth and across the entire Rivers ecosystem.

Canopy Rivers is led by an experienced team of qualified financial and technical professionals with deep industry experience and relationship networks. The company’s acting CEO and chairman is Bruce Linton, CEO of Canopy Growth and founder of Tweed Marijuana.

Canopy Rivers Inc. (CNPOF), closed Tuesday's trading session at $0.6334, up 2.668%, on 75,704 volume with 63 trades. The average volume for the last 3 months is 65,273 and the stock's 52-week low/high is $0.371499985/$2.08949995.

Recent News

chart

DarioHealth Corp. (NASDAQ: DRIO)

The QualityStocks Daily Newsletter would like to spotlight DarioHealth Corp. (DRIO).

New York and Israel-based DarioHealth Corp. (NASDAQ: DRIO) leads global digital therapeutics (DTx) with its popular, smartphone-centered personalized chronic illness management software-as-a-service (SaaS). The company’s strategic advantages include:

  • AI-powered digital solutions that drive durable behavior change in chronic disease patients, and
  • Personalized user experience at scale to make behavior change the path of least resistance.

Approximately $3 trillion in annual U.S. costs associated with chronic illnesses like diabetes, hypertension and obesity are largely preventable with behavioral therapies. Formerly limited to periodic office visits, these therapies can now scale to millions with tech-enabled, continual and remote health monitoring, as well as AI-driven digital and live coaching. This is all possible while still maintaining the personalization required for success in reducing illness and its related effects and costs.

Roughly 51,000 active, paying users manage their health with Dario’s platform that combines smartphone-connected vitals measurement, remote patient monitoring (RPM), lifestyle management tools, and AI-driven and human coaching to deliver improved clinical outcomes.

Among the most downloaded medical apps, the Dario platform is rated at 4.9 stars on the Apple App Store and features 11,000 reviews, along with a Net Promoter Score (a measurement of consumers’ willingness to recommend the product to others) that’s the highest in its field.

Company Strategy

Clinical studies demonstrate Dario’s direct improvement on users’ health measures like H1AC scores (diabetes) and blood pressure (hypertension).

Patient engagement in therapies leads to health success. Dario’s platform centers on continual maximization of patient engagement through personalization, including ‘nudges’ and live, AI-generated responses to health measures provided by Dario’s smartphone-connected medical devices.

Proprietary data analysis provides valuable insights that not only improve health care providers’ medical capabilities but, through artificial intelligence, encourage patients to take evidence-based and highly personalized preventative measures that reduce risk, emergency room visits and preventable hospitalization.

Dario is now deploying its successful B2C platform in B2B2C, targeting employers and health plans with competitive advantages in cost, software and hardware.

The company estimates an annual addressable U.S. market of $72 billion, only 1% of which has been penetrated with digital therapeutics.

The strategic transition to B2B2C (from exclusively B2B) is intended to accelerate revenue growth by reducing Dario’s cost per acquisition per user and expanding margins.

Dario’s commitment to aggressive growth is also shown by its appointment of a new president, chief medical officer and head of sales for North America, all from a highflyer behavioral health company.

Key growth drivers planned include expansion of the company’s paying B2C subscriber base; lateral expansion into other chronic conditions that overlap with its core diabetes populations, such as hypertension, obesity and depression; and increased B2B2C penetration.

Financial Highlights

The company plans to leverage a massive opportunity for growth, with a global addressable market for digital therapeutics of roughly $108 billion. In the U.S. alone, that number is estimated at $72 billion, and only about 1% of that market has been penetrated.

Dario’s strategic transition to an SaaS membership business model increased gross profit by 87% in Q1 2020, as compared to the prior year. Membership revenue increased from 27.1% to 46.7% in the same period. The company is seeing improved operating efficiencies as it shifts focus to the B2B2C business model, and it expects average revenue per user per month (ARPU), which was $6 and $25 in 2019 and 2020, respectively, to reach $70.

Value to Consumers and Businesses

Dario continually evaluates and optimizes the value and return its platform delivers to consumers and businesses.

Consumers seeking to understand how their everyday behavior impacts their personal health and chronic conditions benefit from actionable feedback on how to improve health and better collaborate with health care providers.

Businesses looking to increase employee satisfaction, loyalty and productivity with fewer health-related absences take advantage of Dario’s services for employers.

Health care providers improve patient compliance using the platform’s interactive services that allow for greater monitoring, which improve engagement with patients at the right times and with the right treatments.

Health plans can leverage DarioHealth’s solutions to improve patient outcomes and lower costs.

Recent Studies

The company recently presented the results of two new studies at the American Diabetes Association’s 80th Scientific Sessions, which showed sustained improvements in blood glucose levels and blood pressure among users of its digital therapeutic platform for chronic diseases. The results of these two studies demonstrate that the use of Dario’s therapeutic platform promotes behavioral modification, enhanced individual engagement and improved clinical outcomes.

Remote Patient Monitoring (RPM) Agreements

The Centers for Medicare & Medicaid Services recently approved RPM codes for Medicare patients, which enables physicians to bill for between-visit patient care.

This simplifies implementation of the company’s open and scalable AI-driven platform and further supports transition to the company’s high-margin, recurring SaaS model targeting B2B2C revenue channels.

Emergency COVID-19 FDA Guidelines Allow Self-Test Blood Glucose Meters

In an effort to preserve personal protective equipment (PPE) and reduce contact between health care providers and patients in hospital settings due to COVID-19, the U.S. Food and Drug Administration (FDA) has recognized that home-use blood glucose meters, including Dario’s smartphone-connected metering device, may be used by patients with diabetes who are hospitalized due to COVID-19 to check their own blood glucose levels and provide the readings to the health care personnel caring for them.

As a result, hospitals can now allow patients to self-test using their Dario blood glucose testing strips and smartphone-connected devices, or hospitals can issue patients Dario devices upon admission for COVID-19-related conditions.

Irregularities in blood glucose levels are suspected as a factor in the increased severity of potentially deadly COVID-19 complications. As such, a high priority is being placed on stabilization of patients’ blood glucose levels.

Awards and Recognition

DarioHealth’s Blood Glucose Monitoring System was voted as the ‘Best Glucometer for Data Management’ by Top Ten Reviews. Jeph Preece, senior editor at Top Ten Reviews, said, “The Dario app is the best data management system that I’ve seen. Compared to apps by popular brands, Dario’s system looks and feels like it’s years ahead of the curve.”

‘The Global Digital Health 100’, an annual award sponsored by the reputable Journal of Health, recognized DarioHealth as a leader among health technology companies demonstrating the greatest potential to change the way that health care is delivered.

DarioHealth Corp. (DRIO), closed Tuesday's trading session at $13.59, off by 11.1184%, on 181,801 volume with 1,339 trades. The average volume for the last 3 months is 220,781 and the stock's 52-week low/high is $3.01999998/$18.834999.

Recent News

chart

Trxade Group Inc. (NASDAQ: MEDS)

The QualityStocks Daily Newsletter would like to spotlight Trxade Group Inc. (NASDAQ: MEDS).

Trxade Group Inc. (NASDAQ: MEDS) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform (www.trxade.com) for transactions between independent pharmacists and drug distributors (B2B); a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

Trxade will leverage and scale its fully integrated model to execute the following growth strategies:

  • Increase share of pharmacist drug purchasing
  • Additional SKUs and expand product breath
  • Partner with Specialty and International Mfg.
  • Expand mail order licenses to all 50 states
  • Scale Delivmeds for consumer delivery nationwide
  • Integration with telemedicine
  • M&A Opportunities within drug value chain

Founded in 2010 and headquartered in Tampa, Florida, Trxade’s overarching corporate strategy is to penetrate the existing retail independent pharmacy marketplace and diversify the company’s pharmaceutical mix with additional specialty and acute care products. Trxade is advancing on this mission by focusing on three key niches in the health care market.

Business-to-Business (B2B)

The $330 billion U.S. pharmaceutical industry is comprised of more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. Roughly 24,000 of these facilities are independent pharmacies, which collectively spend approximately $93 billion a year on branded and generic drugs.

Trxade targets these independent pharmacies, leveraging a robust, “E-Bay/Kayak-like” technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

Trxade currently serves and transacts with more than one-third (10,250) of these independent pharmacies and facilitates over $10 million of drug purchases a month!

Consumer

Trxade also targets the “consumer side” of the pharmaceutical industry, aiming to lower prescription drug costs by attacking the inefficient value chain; offering drug price transparency and efficient buying; and, delivering drugs DIRECT to independent pharmacists and consumers.

The company operates a full-service mail order pharmacy for U.S. consumers, as well as a mobile app called “Delivmeds” (http://www.delivmeds.com) which enables SAME DAY home delivery of dispensed prescriptions.

Retail

Trxade’s Managed Services Organization (“TrxadeMSO”) enables its member independent retail pharmacies to get patients, process orders, and deliver or ship prescriptions to patients. TrxadeMSO provides access to encompassing network of pharmacies through the E-Hub software, allowing for timely and comprehensive medication fulfillment.

These offerings ensure the best-suited pharmacy receives the patient’s information, thereby ensuring appropriate medication coverage based on the patient’s location, payor coverage, and medication access/inventory. This will save the clinicians and their staff time as they benefit from efficiency and enhanced workflow management in script processing and fulfillment.

Health Care Market

The U.S. health care market currently hovers near $4 trillion and is expected to grow as the general population ages. This growth will have greater impact on consumers as out-of-pocket expenses also rise. Additionally, drug costs are paced to increase faster than the overall health care and well above inflation.

Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

Trxade’s fair online market platform targets the nation’s retail community and independent pharmacies, of which there are approximately 24,000 nationwide. TRxADE has found that independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The TRxADE S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving money by taking advantage of best purchase pricing.

TRxADE’s programs include:

  • TRxADE Exchange, which opens and widens the distribution channel to the retail, community pharmacy. A purchasing pharmacy can view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. This approach significantly enhances the competitive spirit of the exchange where the lowest price exists for each product at any given point in time. TRxADE has become a competitive tool for all progressive entities and is recognized for its easy searching of hard-to-find generic pharmaceuticals at substantially reduced prices.  
  • RX Guru™ is an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks (“PAC”) to ascertain trends and pricing variances that result in significant purchasing opportunities. RX Guru affords members the opportunity to continuously benefit from real price purchasing opportunities that are concealed from the rest of the industry. 
  • Product Shortage Database – TRxADE maintains the most comprehensive retail, specialty and acute care pharmaceutical product shortage database in the country. Other industry competitors mainly restrict their efforts to specialty and acute care product shortages and narrowly research oral generic products. TRxADE’s advanced prediction tools help members source those hard-to-find products at affordable costs in a timely and easy-to-search process. 

Management Team 

Trxade’s management team is rich in expertise within the pharmaceutical supply chain and is supported by a base of advisors and contractors who are experts in related fields of the pharmaceutical sector.

Suren Ajjarapu – Chairman of the Board, Chief Executive Officer and Secretary
Suren Ajjarapu has served as Trxade’s chairman of the board, CEO and secretary since 2014, and as the chairman of the board, chief executive officer and secretary of Trxade Nevada since its inception. Ajjarapu also serves as a chairman of the board for Feeder Creek Group Inc., since March 2018. Ajjarapu formerly was a founder, CEO and chairman of Sansur Renewable Energy Inc., a company involved in developing wind power sites in the Midwest, United States; a founder, president and director of Aemetis Inc., a biofuels company (AMTX.OB); a founder, chairman and CEO of International Biofuels, a subsidiary of Aemetis Inc.; and a co-founder, COO, and director at Global Information Technology Inc., an IT outsourcing and systems design company. Ajjarapu holds an M.S. in environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in international finance and management. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel – Director, President and Chief Operating Officer
Prashant Patel has served as Trxade’s full-time president and COO, and as a director since the company’s acquisition of Trxade Nevada in 2014, and as the COO and president and as a director of Trxade Nevada since its inception. He has been a president and member of the board of Trxade since August 2010. Patel is a registered pharmacist and pharmaceutical consultant with over 10 years of experience in retail pharmacy and pharmaceutical logistics. He is the founder of several pharmacies in the Tampa Bay area, in Florida. Since 2008, Patel has been managing member of the APAA LLC pharmacy. Since 2007, Patel has been a vice president of Holiday Pharmacy Inc. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

Trxade Group Inc. (MEDS), closed Tuesday's trading session at $6.25, off by 9.2888%, on 113,574 volume with 559 trades. The average volume for the last 3 months is 50,398 and the stock's 52-week low/high is $4.01000022/$11.6000003.

Recent News

chart

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Tuesday's trading session at $2.10, off by 2.7778%, on 9,588 volume with 19 trades. The average volume for the last 3 months is 18,946 and the stock's 52-week low/high is $0.600600004/$4.48999977.

Recent News

chart

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon-free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

 

Energy Fuels Inc. (UUUU), closed Tuesday's trading session at $1.68, off by 5.0847%, on 935,472 volume with 2,689 trades. The average volume for the last 3 months is 1,498,290 and the stock's 52-week low/high is $0.779999971/$2.3499999.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.